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###### Summary of findings table 1

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- ---------------------------------- -------------------------------------- --------------------------
  **Malaria chemoprevention for pregnant women (parity 0‐1) living in endemic areas: maternal outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  **Patient or population:** Pregnant women (parity 0‐1)  **Settings:** Malaria‐endemic areas  **Intervention:** Malaria chemoprevention (any regimen)  **Control:** Placebo or no intervention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**   **Relative effect  (95% CI)**     **No of participants  (trials)**   **Quality of the evidence  (GRADE)**   
  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                      
  **Control**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Chemoprevention**                                                                                                                                         
  **Mortality**   All‐cause death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **7 per 1000**                                  **8 per 1000**   (3 to 20)        **RR 1.15**   (0.44 to 3.06)       2097  (3 trials)                       ⊕⊝⊝⊝  **very low**^1,2^
  **Severe anaemia**   During the third trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **145 per 1000**                                **87 per 1000**   (68 to 108)     **RR 0.60**   (0.47 to 0.75)       2503  (3 trials)                       ⊕⊕⊕⊕  **high**^3,4,5,6^
  **Anaemia**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **649 per 1000**                                **539 per 1000**   (480 to 604)   **RR 0.83**   (0.74 to 0.93)       3662  (5 trials)                       ⊕⊕⊕⊕  **high**^3,6,7,8^
  **Uncomplicated clinical malaria**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **173 per 1000**                                **64 per 1000**   (31 to 128)     **RR 0.37**   (0.18 to 0.74)       307  (2 trials)                        ⊕⊕⊝⊝  **low**^4,9,10^
  **Antenatal parasitaemia**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                **286 per 1000**                                **111 per 1000**   (74 to 165)    **RR 0.39**   (0.26 to 0.58)       3663  (8 trials)                       ⊕⊕⊕⊕  **high**^3,6,7,11^
  **Severe adverse effects**^12^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ‐                                               ‐                                 ‐                                  ‐                                      ‐
  \*The basis for the **assumed risk** (eg, the median control group risk across trials) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** Confidence interval; **RR:** Risk ratio.                                                                                                                                                                                                                                                                                                                                                                 
  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- ---------------------------------- -------------------------------------- --------------------------

^1^ Downgraded by 1 for risk of bias: Only one of these trials adequately described allocation concealment to be considered at low risk of selection bias.  ^2^ Downgraded by 2 for imprecision: These trials were not adequately powered to detect a difference in mortality. Only 15 deaths occurred in these three trials.To confidently detect a 25% reduction in maternal mortality in a setting of 350 deaths/100,000 would require a sample size of over 100,000.  ^3^ No serious risk of bias: Exclusion of the trials at high risk of bias did not change the statistical significance or clinical importance of the result.  ^4^ No serious inconsistency: This finding was consistent across all trials and statistical heterogeneity was low.  ^5^ No serious indirectness: These trials were conducted in Kenya and Mozambique between 1996 and 2005, all three trials administered IPT with SP. The definition of severe anaemia was variable; Hb \< 8 g/dL, Hb \< 7 g/dL, or PCV \< 21%.  ^6^ No serious imprecision: This result is statistically significant and the meta‐analysis is adequately powered to detect this effect.  ^7^ No serious inconsistency: Although statistical heterogeneity was high, all trials favoured chemoprevention but there was variability in the size of the effect.  ^8^ No serious indirectness: These trials were conducted in Nigeria, Kenya and Uganda between 1978 and 1999. Three trials administered IPT as SP, one gave weekly chloroquine, and one gave daily proguanil. The definition of anaemia was variable: Hb \< 12 g/dL, Hb \< 11 g/dL, Hb \< 10 g/dL, PCV \< 33% and PCV \< 30%.  ^9^ Downgraded by 1 for risk of bias. Both trials had high or unclear risk of selection bias and an attrition rate above 20%.  ^10^ Downgraded by 1 for indirectness: Both these trials, from Cameroon 1993 and Mozambique 2002, measured fever history only as proxy for malaria illness.  ^11^ Not downgraded for inconsistency. Despite substantive quantitative heterogeneity (I^2^ 69% across six trials), all show at least a reduction of 23%, often more  ^11^ No serious indirectness: These trials were conducted in The Gambia, Nigeria, Kenya and Mozambique between 1978 and 2005. Five trials gave IPT as SP, one gave pyrimethamine‐dapsone, one pyrimethamine, and one proguanil.  ^12^ Reporting of adverse events was generally poor. No severe adverse events were reported.

###### Summary of findings table 2

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ---------------------------------- -------------------------------------- -----------------------------
  **Malaria chemoprevention for pregnant women (parity 0‐1) living in endemic areas: infant outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Patient or population:** Pregnant women (parity 0‐1)  **Settings:** Malaria‐endemic areas  **Intervention:** Malaria chemoprevention (any regimen)  **Control:** Placebo or no intervention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**                  **Relative effect  (95% CI)**                                                                               **No of participants  (trials)**   **Quality of the evidence  (GRADE)**   

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                                                                                                               

  **Control**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Chemoprevention**                                                                                                                                                                                                                                  

  **Spontaneous abortion**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **33 per 1000**                                                **21 per 1000**   (13 to 33)                                                                                **RR 0.65**   (0.41 to 1.02)       2876  (5 trials)                       ⊕⊕⊝⊝  **low**^1,2,3,4^

  **Stillbirth**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            **33 per 1000**                                                **32 per 1000**   (21 to 49)                                                                                **RR 0.97**   (0.64 to 1.49)       2703  (3 trials)                       ⊕⊕⊝⊝  **low**^2,4,5,6,^

  **Perinatal mortality**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   **104 per 1000**                                               **76 per 1000**   (56 to 104)                                                                               **RR 0.73**   (0.54 to 1.00)       1620  (2 trials)                       ⊕⊕⊝⊝  **low**^2,4,5,7,^

  **Neonatal mortality**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    **37 per 1000**                                                **23 per 1000**   (14 to 39)                                                                                **RR 0.62**   (0.37 to 1.05)       2156  (2 trials)                       ⊕⊕⊝⊝  **low**^2,4,5,7,^

  **Preterm birth**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **164 per 1000**                                               **140 per 1000**   (108 to 181)                                                                             **RR 0.85**   (0.66 to 1.10)       1493  (2 trials)                       ⊕⊕⊝⊝  **low**^1,2,4^

  **Low birthweight**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       **152 per 1000**                                               **110 per 1000**   (92.7 to 132.2)                                                                          **RR 0.73**   (0.61 to 0.87)       3619  (8 trials)                       ⊕⊕⊕⊝  **moderate**^9,10^

  **Mean birthweight**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      The mean birthweight in the control groups ranged from\        The mean birthweight in the intervention groups was  **92.72 g higher**   (62.05 higher to 123.39 higher)   ‐                                  3936  (9 trials)                       ⊕⊕⊕⊝  **moderate**^5,10^
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            **2723 g to 3079 g**                                                                                                                                                                                                                                 

  **Placental parasitaemia**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                **307 per 1000**                                               **160 per 1000**   (132 to 211)                                                                             **RR 0.54**   (0.43 to 0.69)       2830  (7 trials)                       ⊕⊕⊕⊕  **high**^3,11,12^

  **Cord blood haemoglobin**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                The mean haemoglobin in the control group was  **15.8 g/dL**   The mean haemoglobin in the intervention groups was  **1.8 g/dL lower**   (3.46 lower to 0.14 lower)        ‐                                  64  (1 trial)                          ⊕⊝⊝⊝  **very low**^1,13,14^

  \*The basis for the **assumed risk** (eg the median control group risk across trials) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** Confidence interval; **RR:** Risk ratio.                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                                                                                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ---------------------------------- -------------------------------------- -----------------------------

^1^ Downgraded by 1 for serious risk of bias: None of the trials described adequate measures to prevent selection bias.  ^2^ No serious inconsistency: The effect is consistent across trials and statistical heterogeneity is low.  ^3^ No serious indirectness: These trials were conducted in The Gambia, Cameroon, Kenya and Mozambique between 1990 and 2002. One gave chemoprevention as weekly chloroquine and four trials gave IPT with SP.  ^4^ Downgraded by 1 for serious imprecision: The 95% CI is wide and sample remains underpowered to detect or rule out an effect.  ^5^ Downgraded by 1 for serious risk of bias: Only one trial adequately described methods to prevent selection bias.  ^6^ No serious indirectness: Trials were conducted in Cameroon and Kenya between 1993 and 1997. One trial gave weekly chloroquine and the others gave IPT as SP.  ^7^ No serious indirectness: The trials were conducted in The Gambia and Kenya between 1984 and 1997. One trial used IPT with SP and one gave pyrimethamine‐dapsone which is no longer in use.  ^8^ No serious indirectness: Both trials were conducted in Kenya and used IPT with SP.  ^9^ Downgraded by 1 for serious risk of bias: Only two of these trials were at low risk of selection bias.  ^10^ No serious indirectness: These trials were conducted in The Gambia, Cameroon, Kenya, Uganda and Mozambique between 1986 and 2005. The majority of trials used IPT with SP.  ^11^ No serious inconsistency: Although statistical heterogeneity was high, all trials favoured chemoprevention but there was variability in the size of the effect.  ^12^ No serious indirectness: These trials were conducted in The Gambia, Cameroon, Kenya, Uganda and Mozambique between 1990 and 2002. The majority of trials used IPT with SP.  ^13^ Downgraded by 1 for serious indirectness: This single trial used a regimen that is no longer in use (proguanil).  ^14^ Downgraded by 1 for serious imprecision: Only a single small trial has evaluated this comparison.

###### Summary of findings table 3

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- ------------------------------------------------------------------------------------------ ---------------------------------- -------------------------------------- ---------------------------
  **Malaria chemoprevention for pregnant women (parity 2+) living in endemic areas: maternal outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  **Patient or population:** Pregnant women (parity 2+)  **Settings:** Malaria‐endemic areas  **Intervention:** Malaria chemoprevention (any regimen)  **Control:** Placebo or no intervention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**       **Relative effect  (95% CI)**                                                              **No of participants  (trials)**   **Quality of the evidence  (GRADE)**   
  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                                                                                   
  **Control**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Chemoprevention**                                                                                                                                                                                                      
  **Mortality**   All‐cause death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **5 per 1000**                                      **7 per 1000**   (2 to 26                                                                  **RR 1.47**   (0.42 to 5.21)       2239  (1 trial)                        ⊕⊝⊝⊝  **very low**^1,2,3^
  **Severe anaemia**   During the third trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **68 per 1000**                                     **65 per 1000**   (28 to 153)                                                              **RR 0.96**   (0.41 to 2.25)       2682  (2 trials)                       ⊕⊕⊝⊝  **low**^1,4,5^
  **Anaemia**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               The mean PCV in the control group was  **30.4 %**   The mean PCV in the intervention group was  **0.3 % higher**   (0.7 lower to 1.3 higher)   ‐                                  244  (1 trial)                         ⊕⊝⊝⊝  **very low**^6,7,8^
  **Uncomplicated clinical malaria**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ‐                                                   ‐                                                                                          ‐                                  ‐  (0 trials)                          ‐
  **Antenatal parasitaemia**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                **108 per 1000**                                    **41 per 1000**   (30 to 54)                                                               **RR 0.38**   (0.28 to 0.50)       3022  (4 trials)                       ⊕⊕⊕⊕  **high**^9,10^
  **Severe adverse events**^11^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ‐                                                   ‐                                                                                          ‐                                  ‐                                      ‐
  \*The basis for the **assumed risk** (eg the median control group risk across trials) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** Confidence interval; **RR:** Risk ratio.                                                                                                                                                                                                                                                                                                                                                                                                                               
  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                                                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- ------------------------------------------------------------------------------------------ ---------------------------------- -------------------------------------- ---------------------------

^1^ No serious risk of bias: These trials are at low risk of bias.  ^2^ Downgraded by 1 for serious indirectness: This single trial was conducted in The Gambia between 2002 and 2004 and administered IPT as monthly SP. The findings may not be easily generalised to elsewhere.  ^3^ Downgraded by 2 for very serious imprecision: Only ten deaths occurred in this trial. Much larger trials would be needed to detect or exclude effects on maternal mortality.  ^4^ No serious indirectness: These two trials were conducted in The Gambia in 2002‐2004 and Mozambique between 2003 and 2005.  ^5^ Downgraded by 2 for very serious imprecision: The 95% CI are very wide and include the possibility of both clinically important benefits and harms.  ^6^ Downgraded by 1 for serious risk of bias: This single trial is at unclear risk of selection bias.  ^7^ Downgraded by 1 for serious indirectness: This trial administered chemoprevention as pyrimethamine‐dapsone which is no longer in use.  ^8^ Downgraded by 1 for serious imprecision: A much larger sample size is required to confidently detect or exclude an effect.  ^9^ No serious risk of bias: Two of the four trials were at low risk of selection bias and exclusion of the other two trials did not change the size of the effect.  ^10^ No serious indirectness: These three trials were conducted in The Gambia, Nigeria and Mozambique between 1986 and 2005. The biggest and most recent trial administered IPT with SP (two doses)

^11^ Reporting of adverse events was generally poor. No severe adverse events were reported.

###### Summary of findings table 4

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- ---------------------------------- -------------------------------------- ---------------------------
  **Malaria chemoprevention for pregnant women (parity 2+) living in endemic areas: infant outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **Patient or population:** Pregnant women (parity 2+)  **Settings:** Malaria‐endemic areas  **Intervention:** Malaria chemoprevention (any regimen)  **Control:** Placebo or no intervention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**   **Relative effect  (95% CI)**   **No of participants  (trials)**   **Quality of the evidence  (GRADE)**   

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                    

  **Control**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Chemoprevention**                                                                                                                                       

  **Spontaneous abortion**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ‐                                               ‐                               ‐                                  ‐\                                     ‐
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               (0 trials)                             

  **Stillbirth**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ‐                                               ‐                               ‐                                  ‐\                                     ‐
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               (0 trials)                             

  **Perinatal deaths**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ‐                                               ‐                               ‐                                  ‐\                                     ‐
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               (0 trials)                             

  **Neonatal mortality**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    **26 per 1000**                                 **38 per 1000**   (23 to 62)    **RR 1.46**\                       2017\                                  ⊕⊝⊝⊝  **very low**^1,2,3^
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            (0.90 to 2.38)                     (1 trial)                              

  **Preterm birth**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ‐                                               ‐                               ‐                                  ‐\                                     ‐
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               (0 trials)                             

  **Low birthweight**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       **60 per 1000**                                 **63 per 1000**   (46 to 85)    **RR 0.86**   (0.63 to 1.17)       2743  (3 trials)                       ⊕⊕⊝⊝  **low**^3,4,5^

  **Mean birthweight**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ‐                                               ‐                               ‐                                  ‐\                                     ‐
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               (0 trials)                             

  **Placental parasitaemia**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ‐                                               ‐                               ‐                                  ‐\                                     ‐
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               (0 trials)                             

  **Cord blood haemoglobin**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ‐                                               ‐                               ‐                                  ‐\                                     ‐
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               (0 trials)                             

  \*The basis for the **assumed risk** (eg the median control group risk across trials) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** Confidence interval; **RR:** Risk ratio.                                                                                                                                                                                                                                                                                                                                                                

  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- ---------------------------------- -------------------------------------- ---------------------------

^1^ No serious risk of bias: This single trial was at low risk of selection bias.  ^2^ Downgraded by 1 for serious indirectness: This single trial was conducted in The Gambia between 2002 and 2004 and administered IPT as monthly SP. The findings may not be easily generalised to elsewhere.  ^3^ Downgraded by 2 for serious imprecision: The 95% CI is very wide and includes clinically important effects and no effect. A much larger sample size is required to confidently detect or exclude an effect.  ^4^ No serious risk of bias: These trials are at low risk of selection bias.  ^5^ No serious indirectness: These trials were conducted in The Gambia, Mozambique, and Uganda between 2002 and 2008.

###### Summary of findings table 5

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- ---------------------------------- -------------------------------------- -----------------------------
  **Malaria chemoprevention for all pregnant women (all parities) living in endemic areas: maternal outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **Patient or population:** Pregnant women (all parities)  **Settings:** Malaria‐endemic areas  **Intervention:** Malaria chemoprevention (any regimen)  **Control:** Placebo or no intervention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**   **Relative effect  (95% CI)**     **No of participants  (trials)**   **Quality of the evidence  (GRADE)**   

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                      

  **Control**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Chemoprevention**                                                                                                                                         

  **Mortality**   All‐cause death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **1 per 1000**                                  **1 per 1000**   (0 to 3)         **RR 0.84**   (0.25 to 2.74)       6026  (4 trials)                       ⊕⊕⊝⊝  **low**^1,2,3^

  **Severe anaemia**   During the third trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **26 per 1000**                                 **5 per 1000**   (1 to 19)        **RR 0.19**   (0.05 to 0.75)       1327  (2 trials)                       ⊕⊕⊝⊝  **low**^2,4,5,6^

  **Anaemia**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **206 per 1000**                                **212 per 1000**   (179 to 253)   **RR 1.03**   (0.87 to 1.23)       3027  (3 trials)                       ⊕⊕⊕⊝  **moderate**^1,2,7,8^

  **Uncomplicated clinical malaria**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **114 per 1000**                                **42 per 1000**   (13 to 140)     **RR 0.37**   (0.11 to 1.23)       3455  (4 trials)                       ⊕⊕⊝⊝  **low**^1,9,10^

  **Antenatal parasitaemia**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                **152 per 1000**                                **106 per 1000**   (67 to 172)    **RR 0.70**   (0.44 to 1.13)       3455  (4 trials)                       ⊕⊕⊝⊝  **low**^1,8,11^

  **Severe adverse effects**^12^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ‐                                               ‐                                 ‐                                  ‐\                                     ‐
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 (0 trials)                             

  \*The basis for the **assumed risk** (eg the median control group risk across trials) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** Confidence interval; **RR:** Risk ratio.                                                                                                                                                                                                                                                                                                                                                                  

  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- ---------------------------------- -------------------------------------- -----------------------------

^1^ No serious risk of bias: The two most recent trials adequately described allocation concealment to be considered at low risk of selection bias.  ^2^ No serious inconsistency: This finding was consistent across all trials and statistical heterogeneity was low.  ^3^ Downgraded by 2 for very serious imprecision: These trials were not adequately powered to detect a difference in mortality. Only nine deaths occurred in these four trials. To confidently detect a 25% reduction in maternal mortality in a setting of 350 deaths/100,000 would require a sample size of over 100,000.  ^4^ No serious risk of bias: One of these two trials adequately described allocation concealment to be at low risk of bias.  ^5^ Downgraded by 1 for serious indirectness: Only a single trial from Mozambique provides data on the currently used regimen of IPT as two doses of SP. The definition of severe anaemia was PCV \<21%.  ^6^ Downgraded by 1 for serious imprecision: The number of events is very low and the trials underpowered to be confident in these results.   ^7^ No serious indirectness: These trials were conducted in Thailand, Mozambique and Uganda between 1988 and 2008. The two recent trials administered IPT as two doses of SP. The definition of anaemia was variable; Hb \< 11 g/dL, PCV \< 33% and PCV \<30%.  ^8^ Downgraded by 1 for serious imprecision: Although the finding is of no effect. The 95% CI includes what may be clinically important differences.  ^9^ Downgraded by 1 for serious inconsistency: The two old trials from 1957 and 1988 suggest clinically important benefits with chemoprophylaxis ‐ however, the two recent trials providing two doses of SP find no evidence of an effect.  ^10^ Downgraded by 1 for serious indirectness: The finding of no effect in the two recent trials may be due to the declining efficacy of two doses of SP.   ^11^ Downgraded for by 1 for serious inconsistency. There is substantive heterogeneity between trials (I^2^ = 79%), and this finding of no effect is in contrast to findings of benefit in both women of low parity and multigravidae. The finding of no effect in two of the recent trials may reflect declining efficacy in the regimens used.  ^12^ Reporting of adverse events was generally poor. No severe adverse events were reported.

###### Summary of findings table 6

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------- -------------------------------------- ------------------------------
  **Malaria chemoprevention for pregnant women (all parities) living in endemic areas: infant outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **Patient or population:** Pregnant women (all parities)  **Settings:** Malaria‐endemic areas  **Intervention:** Malaria chemoprevention (any regimen)  **Control:** Placebo or no intervention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**             **Relative effect  (95% CI)**                                                                             **No of participants  (trials)**   **Quality of the evidence  (GRADE)**   

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                                                                                                        

  **Control**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Chemoprevention**                                                                                                                                                                                                                           

  **Spontaneous abortion**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **12 per 1000**                                           **11 per 1000**   (7 to 16)                                                                               **RR 0.89**   (0.58 to 1.36)       5767  (3 trials)                       ⊕⊕⊝⊝  **low**^1,2,3,4^

  **Stillbirth**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            **22 per 1000**                                           **22 per 1000**   (17 to 30)                                                                              **RR 1.02**   (0.76 to 1.36)       7130  (5 trials)                       ⊕⊕⊕⊝  **moderate**^1,2,5^

  **Perinatal mortality**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   **33 per 1000**                                           **41 per 1000**   (31 to 54)                                                                              **RR 1.24**   (0.94 to 1.63)       5216  (4 trials)                       ⊕⊕⊕⊝  **moderate**^1,2,5^

  **Neonatal mortality**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    **62 per 1000**                                           **56 per 1000**   (44 to 72)                                                                              **RR 0.91**   (0.71 to 1.16)       6313  (5 trials)                       ⊕⊕⊕⊝  **moderate**^1,2,5^

  **Preterm birth**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **85 per 1000**                                           **81 per 1000**   (55 to 117)                                                                             **RR 0.95**   (0.65 to 1.38)       1174  (2 trials)                       ⊕⊕⊝⊝  **low**^2,5,6,10^

  **Low birthweight**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       **119 per 1000**                                          **126 per 1000**   (106 to 151)                                                                           **RR 1.06**   (0.89 to 1.27)       3644  (4 trials)                       ⊕⊕⊝⊝  **low**^1,2,5,10^

  **Mean birthweight**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      The mean birthweight in the control groups ranged from\   The mean birthweight in the intervention groups was  **0.54 g lower**   (24.6 g lower to 23.6 g higher)   ‐                                  6007  (5 trials)                       ⊕⊕⊕⊝  **moderate**^1,7,8,10^
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            **2797 g to 3161 g**                                                                                                                                                                                                                          

  **Placental parasitaemia**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                **181 per 1000**                                          **80 per 1000**   (27 to 233)                                                                             **RR 0.44**   (0.15 to 1.29)       3200  (4 trials)                       ⊕⊕⊝⊝  **low**^1,9,10^

  \*The basis for the **assumed risk** (eg the median control group risk across trials) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** Confidence interval; **RR:** Risk ratio.                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                                                                                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------- -------------------------------------- ------------------------------

^1^ No serious risk of bias: The two most recent trials adequately described allocation concealment to be considered at low risk of selection bias.  ^2^ No serious inconsistency: The finding of no difference is consistent across trials and statistical heterogeneity is low  ^3^ No serious indirectness: These trials were conducted in the Burkina Faso, Mozambique and Uganda between 1988 and 2008. One gave chemoprevention as weekly chloroquine and two trials gave IPT with SP.  ^4^ Downgraded by 2 for very serious imprecision: The 95% CI is wide and sample remains underpowered to detect or rule out an effect.  ^5^ Downgraded by 1 for serious imprecision: The 95% CI is wide and sample remains underpowered to detect or rule out an effect.  ^6^ No serious risk of bias: The most recent trial adequately described allocation concealment to be considered at low risk of selection bias.  ^7^ No serious inconsistency: Although substantial statistical heterogeneity is present (I^2^ = 72%), this relates to the oldest trial which found a benefit with chemoprevention. The subsequent four trials have consistently found no clinically important difference.  ^8^ No serious imprecision: The 95% CI probably excludes clinically important benefits.  ^9^ Downgraded by 1 for serious inconsistency: The two old trials from 1957 and 1988 suggest clinically important benefits with chemoprophylaxis ‐ however, the two recent trials providing two doses of SP find no evidence of an effect.  ^10^ Downgraded by 1 for serious indirectness: The finding of no effect in the recent trials may be due to the declining efficacy of two doses of SP which is no longer recommended.

###### Summary of findings table 7

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- ---------------------------------- -------------------------------------- -----------------------------
  **Intermittent preventive treatment with SP for pregnant women (parity 0‐1) living in malaria endemic areas: maternal outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  **Patient or population:** Pregnant women (parity 0‐1)  **Settings:** Malaria‐endemic areas  **Intervention:** Intermittent preventive treatment with SP (2 doses, 3 doses, or monthly dosing)  **Control:** Placebo or no intervention                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**   **Relative effect  (95% CI)**     **No of participants  (trials)**   **Quality of the evidence  (GRADE)**   

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                      

  **Control**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **IPT (SP)**                                                                                                                                                

  **Mortality**   All‐cause death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **7 per 1000**                                  **8 per 1000**   (3 to 20)        **RR 1.15**   (0.44 to 3.06)       2097  (2 trials)                       ⊕⊝⊝⊝  **very low**^1,2^

  **Severe anaemia**   During the third trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **145 per 1000**                                **87 per 1000**   (68 to 108)     **RR 0.60**   (0.47 to 0.75)       2503  (3 trials)                       ⊕⊕⊕⊕  **high**^3,4,5,6^

  **Anaemia**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **617 per 1000**                                **543 per 1000**   (480 to 604)   **RR 0.88**   (0.81 to 0.96)       3291  (4 trials)                       ⊕⊕⊕⊝  **moderate**^1,6,7,8^

  **Uncomplicated clinical malaria**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **9 per 100**                                   **2 per 100**   (0 to 10)         **RR 0.24**   (0.05 to 1.12)       174  (1 trial)                         ⊕⊝⊝⊝  **very low**^9,10,11^

  **Antenatal parasitaemia**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                **286 per 1000**                                **108 per 1000**   (69 to 169)    **RR 0.38**   (0.24 to 0.59)       2832  (4 trials)                       ⊕⊕⊕⊕  **high**^3,6,7,12^

  **Severe adverse effects**^13^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ‐                                               ‐                                 ‐                                  ‐\                                     ‐
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 (0 trials)                             

  \*The basis for the **assumed risk** (eg the median control group risk across trials) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** Confidence interval; **RR:** Risk ratio.                                                                                                                                                                                                                                                                                                                                                                  

  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- ---------------------------------- -------------------------------------- -----------------------------

^1^ Downgraded by 1 for risk of bias: Only one of these trials adequately described allocation concealment to be considered at low risk of selection bias.  ^2^ Downgraded by 2 for imprecision: These trials were not adequately powered to detect a difference in mortality. Only 15 deaths occurred in these two trials. To confidently detect a 50% reduction in maternal mortality in a setting of 350 deaths/100,000 would require a sample size of over 100,000.  ^3^ No serious risk of bias: Exclusion of the trials at high risk of bias did not change the statistical significance or clinical importance of the result.  ^4^ No serious inconsistency: This finding was consistent across all trials and statistical heterogeneity was low.  ^5^ No serious indirectness: These trials were conducted in Kenya and Mozambique between 1996 and 2005, all three trials administered IPT with SP. The definition of severe anaemia was variable; Hb \< 8 g/dL, Hb \< 7g/dL, or PCV \< 21%.  ^6^ No serious imprecision: This result is statistically significant and the meta‐analysis is adequately powered to detect this effect.  ^7^ No serious inconsistency: Although statistical heterogeneity was high, all trials favoured IPT with SP but there was variability in the size of the effect.  ^8^ No serious indirectness: These trials were conducted Kenya between 1996 and 1999. The definition of anaemia was variable; Hb \< 11 g/dL, Hb \< 10 g/dL.  ^9^ Downgraded by 1 for risk of bias: This trial is at unclear risk of selection bias.  ^10^ Downgraded by 1 for indirectness: This trial from Mozambique 2002, measured fever history only as proxy for malaria illness.  ^11^ Downgraded by 1 for serious imprecision: The 95% CI is wide and includes clinically important benefits and no effect.  ^12^ No serious indirectness: These trials were conducted in the Kenya and Mozambique between 1996 and 2005.  ^13^Reporting of adverse events was generally poor. No severe adverse events were reported.

###### Summary of findings table 8

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- -------------------------------------------------------------------------------------------------- ---------------------------------- -------------------------------------- --------------------------
  **Intermittent preventive treatment with SP for pregnant women (parity 0‐1) living in malaria endemic areas: infant outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Patient or population:** Pregnant women (parity 0‐1)  **Settings:** Malaria‐endemic areas  **Intervention:** Intermittent preventive treatment with SP (2 doses, 3 doses, or monthly dosing)  **Control:** Placebo or no intervention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**             **Relative effect  (95% CI)**                                                                      **No of participants  (trials)**   **Quality of the evidence  (GRADE)**   

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                                                                                                 

  **Control**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **IPT (SP)**                                                                                                                                                                                                                           

  **Spontaneous abortion**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **34 per 1000**                                           **21 per 1000**   (13 to 33)                                                                       **RR 0.61**   (0.38 to 0.99)       2567  (3 trials)                       ⊕⊕⊝⊝  **low**^1,2,3,4^

  **Stillbirth**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            **33 per 1000**                                           **32 per 1000**   (21 to 49)                                                                       **RR 0.97**   (0.64 to 1.47)       2703  (3 trials)                       ⊕⊕⊝⊝  **low**^2,4,5,6^

  **Perinatal mortality**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   **80 per 1000**                                           **62 per 1000**   (42 to 94)                                                                       **RR 0.78**   (0.52 to 1.17)       1237  (1 trial)                        ⊕⊕⊝⊝  **low**^7^

  **Neonatal mortality**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    **37 per 1000**                                           **23 per 1000**   (14 to 39)                                                                       **RR 0.62**   (0.37 to 1.05)       2156  (2 trials)                       ⊕⊕⊝⊝  **low**^2,4,5,6^

  **Preterm birth**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **164 per 1000**                                          **140 per 1000**   (108 to 181)                                                                    **RR 0.85**   (0.66 to 1.10)       1493  (2 trials)                       ⊕⊕⊝⊝  **low**^1,2,4^

  **Low birthweight**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       **128 per 1000**                                          **104 per 1000**   (86 to 127)                                                                     **RR 0.81**   (0.67 to 0.99)       3043  (4 trials)                       ⊕⊕⊕⊝  **moderate**^8,9^

  **Mean birthweight**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      The mean birthweight in the control groups ranged from\   The mean birthweight in the intervention groups was  **84.18 g higher**   (40.1 to 128.3 higher)   ‐                                  2127  (3 trials)                       ⊕⊕⊕⊝  **moderate**^5,9^
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            **2908 g to 3079 g**                                                                                                                                                                                                                   

  **Placental parasitaemia**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                **225 per 1000**                                          **101 per 1000**   (74 to 137)                                                                     **RR 0.45**   (0.33 to 0.61)       1633  (3 trials)                       ⊕⊕⊕⊝  **moderate**^5,10^

  **Cord blood haemoglobin**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ‐                                                         ‐                                                                                                  ‐                                  ‐\                                     ‐
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            (0 trials)                             

  \*The basis for the **assumed risk** (eg the median control group risk across trials) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** Confidence interval; **RR:** Risk ratio.                                                                                                                                                                                                                                                                                                                                                                                                                                             

  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                                                                                                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- -------------------------------------------------------------------------------------------------- ---------------------------------- -------------------------------------- --------------------------

^1^ Downgraded by 1 for serious risk of bias: None of the trials described adequate measures to prevent selection bias.  ^2^ No serious inconsistency: The effect is consistent across trials and statistical heterogeneity is low  ^3^ No serious indirectness: These trials were conducted in the Kenya and Mozambique between 1996 and 2002.  ^4^ Downgraded by 1 for serious imprecision: The 95% CI is wide and sample remains underpowered to detect or rule out an effect.  ^5^ Downgraded by 1 for serious risk of bias: Only one trial adequately described methods to prevent selection bias.  ^6^ No serious indirectness: Trials were conducted in Kenya between 1996 and 1997.  ^7^ Downgraded by 2 for serious imprecision: The 95% CI is wide and sample remains underpowered to detect or rule out an effect.  ^8^ Downgraded by 1 for serious risk of bias: Only two of these trials were at low risk of selection bias.  ^9^ No serious indirectness: These trials were conducted in the Kenya, Uganda and Mozambique between 1996 and 2008.  ^10^ No serious inconsistency: Although statistical heterogeneity was high, all trials favoured chemoprevention but there was variability in the size of the effect.

Background {#CD000169-sec1-0002}
==========

Description of the condition {#CD000169-sec2-0001}
----------------------------

Approximately 125 million women living in malaria‐endemic areas become pregnant each year ([Dellicour 2010](#CD000169-bbs2-0051){ref-type="ref-list"}), and pregnancy is known to increase the risk of malaria infection and the severity of the illness compared to non‐pregnant women in the same age group ([Desai 2007](#CD000169-bbs2-0052){ref-type="ref-list"}). Studies have also shown a strong association between malaria infection in pregnancy and consequent maternal anaemia, and low birthweight in infants, particularly in women in their first or second pregnancy ([Desai 2007](#CD000169-bbs2-0052){ref-type="ref-list"}; [Steketee 2001](#CD000169-bbs2-0062){ref-type="ref-list"}).

To reduce the burden and consequences of malaria in pregnancy, the World Health Organization (WHO) recommends that all pregnant women living in malaria‐endemic areas: i) sleep under a long lasting insecticide‐treated bednet (ITN; [Gamble 2006](#CD000169-bbs2-0054){ref-type="ref-list"}; [WHO 2012](#CD000169-bbs2-0067){ref-type="ref-list"}); ii) are treated when anaemic or when ill with malaria; and iii) receive some form of malaria chemoprevention. Currently the WHO recommends \'intermittent‐preventive therapy\' with sulfadoxine‐pyrimethamine (SP) during the second and third trimesters in Africa ([WHO 2013](#CD000169-bbs2-0068){ref-type="ref-list"}).

Description of the intervention {#CD000169-sec2-0002}
-------------------------------

Over the years a variety of drugs have been evaluated for malaria chemoprevention in pregnancy, including amodiaquine, chloroquine, dapsone‐pyrimethamine, mefloquine, proguanil, pyrimethamine as monotherapy and as the fixed dose combination SP, and others. All have specific toxic and adverse effects, which are outlined in standard texts ([WHO 2010](#CD000169-bbs2-0066){ref-type="ref-list"}), and these may be important factors influencing maternal adherence. For example, proguanil can cause mouth ulcers, chloroquine can cause itch, and mefloquine can cause dizziness and headaches.

How the intervention might work {#CD000169-sec2-0003}
-------------------------------

Chemoprevention encompasses malaria chemoprophylaxis, and also the use of treatment courses given regularly to women. This is termed intermittent preventive treatment (IPT), defined as a full therapeutic course of antimalarial medicine given to pregnant women at routine prenatal visits, regardless of whether the recipient is infected with malaria. combines elements of a treatment effect through clearance or suppression of existing malaria infections in the placental and peripheral blood of mother, and a post‐treatment prophylactic effect by preventing new infections for several weeks after each dose ([White 2005](#CD000169-bbs2-0065){ref-type="ref-list"}). Daily, weekly, or bi‐weekly malaria chemoprophylaxis is thought to work primarily through the prevention of new malaria infections. However, a reduction in malaria infections per se may be insufficient to justify the use of chemoprevention for widespread use without subsequent benefits on clinically important outcomes in the mother and her baby. These may include a reduction in clinical malaria episodes, a reduced risk of anaemia, improved birthweight, or more substantive outcomes such as a reduction in severe maternal illness, or fewer deaths in the mother and infant (see [Figure 1](#CD000169-fig-0001){ref-type="fig"}).

![Drugs for preventing malaria in pregnancy: conceptual framework.](nCD000169-AFig-FIG01){#CD000169-fig-0001}

The effects of malaria chemoprevention may differ between settings dependent on the local malaria epidemiology. In highly endemic areas with stable transmission, mothers may have partial immunity to malaria, and chronic subclinical placental infection are common leading to maternal anaemia and low birthweight, especially in primi‐ and secundigravidae. In contrast, where malaria transmission is low or unstable, the degree of life‐long acquired and pregnancy‐specific protective immunity may be lower and malaria infections are more likely to result in clinical episodes or severe illness, leading to low birthweight due to a preterm birth, foetal loss or maternal death.

Another potential effect modifier is HIV status. Many malaria‐endemic areas, especially in east and southern Africa, also have a high prevalence of HIV infection among pregnant women. Compared to HIV negative women, HIV positive women are more likely to carry malaria parasites in their blood, have higher parasite densities, and are more likely to have placental parasitaemia, anaemia, and malaria symptoms and deliver low birthweight babies ([Nkhoma 2012a](#CD000169-bbs2-0059){ref-type="ref-list"}; [Nkhoma 2012b](#CD000169-bbs2-0060){ref-type="ref-list"}; [ter Kuile 2004](#CD000169-bbs2-0063){ref-type="ref-list"}).

Why it is important to do this review {#CD000169-sec2-0004}
-------------------------------------

This Cochrane Review aims to address the following questions:

Does chemoprevention reduce mortality and substantive outcomes in the mother and infant?What is the potential reduction in the burden of malaria in pregnancy that can be achieved by successful malaria chemoprevention in pregnancy?Are the effects consistent in low parity and high parity women?

This review summarises the underpinning evidence of the protective efficacy achieved with antimalarial chemoprevention regimens on the effects on malaria and its consequences on the mother and baby when compared against placebo or no chemoprevention (case‐management strategies only). It does not compare different regimens. These were included in earlier editions of this Cochrane Review ([Garner 2006](#CD000169-bbs2-0073){ref-type="ref-list"}); a more recent review has examined the effects of different IPT regimens in pregnant women ([Kayentao 2013](#CD000169-bbs2-0057){ref-type="ref-list"}).

Objectives {#CD000169-sec1-0003}
==========

In malaria‐endemic areas, to assess the effects in pregnant women of:

Malaria chemoprevention versus no chemoprevention irrespective of the regimen;Malaria chemoprevention with SP (called intermittent preventive treatment) with no chemoprevention;Preventive regimens for *Plasmodium vivax*.

Methods {#CD000169-sec1-0004}
=======

Criteria for considering studies for this review {#CD000169-sec2-0005}
------------------------------------------------

### Types of studies {#CD000169-sec3-0001}

Randomized controlled trials (RCTs) and quasi‐RCTs.

### Types of participants {#CD000169-sec3-0002}

Pregnant women of any gravidity living in malaria‐endemic areas, defined as regions where transmission occurs and malaria is a characteristic of the region.

### Types of interventions {#CD000169-sec3-0003}

#### Interventions {#CD000169-sec4-0001}

Any antimalarial drug chemoprevention regimen given to pregnant women.

#### Controls {#CD000169-sec4-0002}

Placebo or no intervention,

### Types of outcome measures {#CD000169-sec3-0004}

For the conceptual framework, see Figure 1.

#### Maternal outcomes {#CD000169-sec4-0003}

[Impact]{.ul}: maternal deaths (number of maternal deaths reported: death of a pregnant woman during pregnancy or within 42 days of termination of pregnancy).[Substantive outcomes:]{.ul} severe malaria, which includes severe anaemia (defined as Hb \< 8 g/dL, \< 7 g/dL, \< 6 g/dL); severe adverse events.[Clinically important outcomes:]{.ul} anaemia (anaemia defined as Hb \< between 10 and 12 g/dL); mean haemoglobin (g/dL) or mean PCV (%); clinical malaria (history of fever episodes prior to delivery); adverse events.[Indicators of malaria infection:]{.ul} parasitaemia (defined as the presence of asexual stage parasites in thick smears in peripheral, placental, or cord blood).

#### Infant outcomes {#CD000169-sec4-0004}

[Impact:]{.ul} neonatal and Infant mortality.[Substantive outcomes:]{.ul} foetal loss (including spontaneous abortion (spontaneous expulsion of a fetus before it is able to survive independently); stillbirth (birth of a foetus with no vital signs, born after the 28th week of pregnancy); perinatal mortality; severe adverse events, including congenital anomalies (a defect that is present at birth).[Clinically important outcomes:]{.ul} preterm birth (delivery at \< 37 weeks gestation); low birthweight (\< 2500 g); mean birthweight; cord blood anaemia; adverse events.[Indicators of malaria infection:]{.ul} placental malaria; haemoglobin levels (infant), cord blood haemoglobin (g/dL), and cord blood PCV; cord blood parasitaemia.

Search methods for identification of studies {#CD000169-sec2-0006}
--------------------------------------------

We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).

### Databases {#CD000169-sec3-0005}

We searched the following databases using the search terms and strategy described in [Appendix 1](#CD000169-sec2-0016){ref-type="app"}: Cochrane Infectious Diseases Group Specialized Register (1 June 2014); Central Register of Controlled Trials (CENTRAL); MEDLINE (1966 to 1 June 2014); EMBASE (1974 to February 2012); and LILACS (1982 to February 2012).

### Researchers {#CD000169-sec3-0006}

We contacted researchers working in the field for unpublished data, confidential reports, and raw data of published trials.

### Reference lists {#CD000169-sec3-0007}

We also checked the citations of literature reviews, and of all trials identified by the above methods, and asked the referees to check the search strategy.

Data collection and analysis {#CD000169-sec2-0007}
----------------------------

### Selection of studies {#CD000169-sec3-0008}

We applied inclusion criteria to all trials, including those in the previous edition of this Cochrane Review. DR‐P and PG independently screened all trials identified by the search strategy ([Appendix 1](#CD000169-sec2-0016){ref-type="app"}). Using a form based on the inclusion criteria, DR‐P and PG assessed eligibility independently. FK checked the completeness of the included trials. We retrieved full text articles for all potentially relevant trials, applied the inclusion criteria, and then compared decisions. We resolved any differences by discussion and, when necessary, consulted with co‐authors.Trials identified in the initial abstract screening which did not meet the inclusion criteria are listed in the \'[Characteristics of excluded studies](#CD000169-sec2-0023){ref-type="sec"}\'.

### Data extraction and management {#CD000169-sec3-0009}

DR‐P and PG independently extracted data using a data extraction form. We extracted data on trial characteristics, including trial site, year, local malaria transmission and resistance, trial methods, participants, interventions, doses and outcomes and entered this data into [Review Manager 5.1](#CD000169-bbs2-0061){ref-type="ref-list"}. The number of participants randomized and the number analysed in the experimental and control arms were extracted in each group for each outcome. For dichotomous outcomes, we recorded the number of participants experiencing the event and the number assessed in each treatment group. For continuous outcomes, we extracted the arithmetic means, standard deviations for each treatment group and the number of participants assessed in each group. We calculated and reported the loss to follow‐up in each group.

### Assessment of risk of bias in included studies {#CD000169-sec3-0010}

We independently assessed the trials\' methodological quality (risk of bias) of each trial, using the Cochrane Collaboration\'s tool for assessing the risk of bias ([Higgins 2011](#CD000169-bbs2-0056){ref-type="ref-list"}). The following six components were assessed for each trial: generation of allocation sequence, allocation concealment, blinding (of participants, personnel, and outcome assessors), incomplete outcome data, selective outcome reporting, and other sources of bias. Each component was classified by \'yes\' (low risk of bias), \'no\' (high risk of bias), or \'unclear\' to indicate level of bias. Where our judgement was \'unclear\', we attempted to contact the trial authors for clarification.

### Measures of treatment effect {#CD000169-sec3-0011}

We used the risk ratio (RR) to summarise dichotomous outcomes, reported the mean difference for continuous outcomes, and used the rate ratio for count outcomes. We presented all measures of effect with 95% confidence intervals (CI). One trial had four arms: one a comparison of IPT with nets, and a second comparison with no nets, and these were treated as separate comparisons ([Njagi 2003i KEN](#CD000169-bbs2-0014){ref-type="ref-list"}; [Njagi 2003ii KEN](#CD000169-bbs2-0013){ref-type="ref-list"}); a second trial had two intervention comparisons, so in meta‐analysis we split the control group in half for dichotomous outcomes. For continuous outcomes, we split the denominator of the control in half, but applied no correction to the standard deviation.

### Unit of analysis issues {#CD000169-sec3-0012}

If the original trial analyses had not adjusted for clustering, we planned to adjust the results for clustering by multiplying the standard errors of the treatment effect by the square root of the design effect. The design effect would be calculated as 1+(m‐1)\*ICC where m was the average cluster size and ICC was the intra‐cluster correlation coefficient. We planned to estimate the ICC from other trials included in the review or by contacting trial investigators. We also planned to include trials with multiple treatment arms if relevant to any of the comparisons. One trial randomized by compound in The Gambia ([Greenwood 1989 GMB](#CD000169-bbs2-0005){ref-type="ref-list"}). However, we know that compounds are quite small, are grouped around families, and that, even if two women were pregnant at the same time in one family, this would not be quantitatively important in terms of overestimating the precision of the effect estimate.

### Dealing with missing data {#CD000169-sec3-0013}

We planned to use intention‐to‐treat (ITT) data from the original trials, but it was more practical to use a complete‐case analysis, such that we excluded participants for whom no outcome was reported from the analysis. This analysis assumes that the participants for whom an outcome is available are representative of the original randomized patients. If data from the trial reports were insufficient, unclear, or missing, we attempted to contact the trial authors for additional information. In one trial with no standard deviation for birthweight, we used the average of the standard deviation for the other included trials.

### Assessment of heterogeneity {#CD000169-sec3-0014}

We inspected the forest plots to detect overlapping CIs, applying the Chi^2^ test and a P value of 0.10 as the cut‐off value to determine statistical significance. We also estimated the I^2^‐statistic and categorized the degree of heterogeneity using standard cut‐offs ([Higgins 2011](#CD000169-bbs2-0056){ref-type="ref-list"}).

### Data synthesis {#CD000169-sec3-0015}

We used [Review Manager 5.1](#CD000169-bbs2-0061){ref-type="ref-list"} for the analysis.

Our primary analysis is stratified by parity, with results grouped into women of low parity (0‐1) and multigravidae (1+).

We included a category called \'all women\'. This included trials that recruited women irrespective of parity. This analysis included the trials which had stratified the analysis by parity (and were therefore included in the primary analysis), and a second set of trials, which had not. This analysis provides information on the population effects of a policy of providing chemoprevention to all pregnant women.

We used RRs for dichotomous variables and mean differences (MD) for continuous variables; all results are presented with 95% CIs. In the absence of heterogeneity, we used a fixed‐effect model for the meta‐analysis, and where we detected heterogeneity we used a random‐effects model. Weighted averages were calculated where required. We converted Packed Cell Volume (PCV) values to haemoglobin values by dividing by three.

### Subgroup analysis and investigation of heterogeneity {#CD000169-sec3-0016}

We grouped the analysis by parity. Although we intended to investigate heterogeneity by a variety of factors (including HIV status, risk of bias, geographical region, malaria transmission pattern, antimalarial resistance, ITN use, drug regimen), there were insufficient data to do this.

Results {#CD000169-sec1-0005}
=======

Description of studies {#CD000169-sec2-0008}
----------------------

### Results of the search {#CD000169-sec3-0017}

The search was conducted up to 01 June 2014 for the time period 1964 to 2014, and identified 181 references of which two were duplicate trial reports. Out of 179, we retrieved 53 full‐text articles for eligibility screening ([Figure 2](#CD000169-fig-0002){ref-type="fig"}).

![Study flow diagram.](nCD000169-AFig-FIG02){#CD000169-fig-0002}

### Included studies {#CD000169-sec3-0018}

Seventeen chemoprevention trials, enrolling 20,256 pregnant women, met our inclusion criteria (see \'[Characteristics of included studies](#CD000169-sec2-0022){ref-type="sec"}\'). These trials were conducted between 1957 and 2008, in Nigeria (three trials), The Gambia (three trials), Kenya (three trials), Mozambique (two trials), Uganda (two trials), Cameroon (one trial), Burkina Faso (one trial), and Thailand (two trials).

Six different antimalarials were evaluated against placebo or no preventive intervention (ie passive case detection and treatment of clinical cases only); chloroquine (given weekly), pyrimethamine (weekly or monthly), proguanil (daily), pyrimethamine‐dapsone (weekly or fortnightly), SP (given twice, monthly or intermittently for up to four doses at least one month apart), and mefloquine (weekly) (see [Appendix 2](#CD000169-sec2-0017){ref-type="app"}). Fifteen trials reported that drug administration was supervised, and in two trials it was unsupervised ([Fleming 1986 NGA](#CD000169-bbs2-0004){ref-type="ref-list"}; [Ndyomugyenyi 2000 UGA](#CD000169-bbs2-0011){ref-type="ref-list"}).

Eight trials recruited women in all parity groups; four reported aggregate results, and four disaggregated by parity. The rest only recruited low parity women: six were parity 0, and two were women of parity 0‐1. One trial only recruited multigravidae (see [Appendix 3](#CD000169-sec2-0018){ref-type="app"}).

In four trials, all women in both intervention and control groups received a long‐lasting ITNs at recruitment ([Menendez 2008 MOZ](#CD000169-bbs2-0008){ref-type="ref-list"}; [Ndyomugyenyi 2000 UGA](#CD000169-bbs2-0011){ref-type="ref-list"}; [Ndyomugyenyi 2011 UGA](#CD000169-bbs2-0012){ref-type="ref-list"}; [Njagi 2003i KEN](#CD000169-bbs2-0014){ref-type="ref-list"}). One additional trial mentioned that ITNs were in use in the area, with a use of 26% ([Shulman 1999 KEN](#CD000169-bbs2-0018){ref-type="ref-list"}; [ter Kuile 2007](#CD000169-bbs2-0064){ref-type="ref-list"}). In six trials iron and folic acid were routinely administered to all pregnant women ([Fleming 1986 NGA](#CD000169-bbs2-0004){ref-type="ref-list"}; [Mbaye 2006 GMB](#CD000169-bbs2-0006){ref-type="ref-list"}; [Nahlen 1989 NGA](#CD000169-bbs2-0010){ref-type="ref-list"}; [Njagi 2003i KEN](#CD000169-bbs2-0014){ref-type="ref-list"}; [Njagi 2003ii KEN](#CD000169-bbs2-0013){ref-type="ref-list"}; [Parise 1998i KEN](#CD000169-bbs2-0017){ref-type="ref-list"}; [Parise 1998ii KEN](#CD000169-bbs2-0016){ref-type="ref-list"}; [Villegas 2007 THA](#CD000169-bbs2-0019){ref-type="ref-list"}), in one trial only iron was administered ([Shulman 1999 KEN](#CD000169-bbs2-0018){ref-type="ref-list"}), and in one trial both iron and folic acid were given to anaemic women ([Nosten 1994 THA](#CD000169-bbs2-0015){ref-type="ref-list"}). The remaining trials did not comment on use of iron or folic acid.

One trial was randomized by compound, but for the analysis we assumed that it was individually randomized ([Greenwood 1989 GMB](#CD000169-bbs2-0005){ref-type="ref-list"}). Two trials with multiple intervention arms were presented by individual arms, and the placebo patients split between the two arms where the treatment arms were both included in the meta‐analysis; [Parise 1998i KEN](#CD000169-bbs2-0017){ref-type="ref-list"} compared two doses of SP versus no intervention while [Parise 1998ii KEN](#CD000169-bbs2-0016){ref-type="ref-list"} compared monthly SP versus no intervention; [Njagi 2003i KEN](#CD000169-bbs2-0014){ref-type="ref-list"} compared SP + ITNs versus placebo + ITNs; and [Njagi 2003ii KEN](#CD000169-bbs2-0013){ref-type="ref-list"} compared SP alone versus placebo.

### Excluded studies {#CD000169-sec3-0019}

We excluded 32 trials for the reasons given in the \'[Characteristics of excluded studies](#CD000169-sec2-0023){ref-type="sec"}\' table. Also in this review update, we excluded one previously included trial ([Hamilton 1972 UGA](#CD000169-bbs2-0030){ref-type="ref-list"}) as iron was administered to one of the control groups and folic acid to the other, but nothing was mentioned of iron and folates being administered to women in the intervention group (chloroquine).

Risk of bias in included studies {#CD000169-sec2-0009}
--------------------------------

See [Figure 3](#CD000169-fig-0003){ref-type="fig"} for a summary of the risk of bias assessments. We have presented further details in the \'[Characteristics of included studies](#CD000169-sec2-0022){ref-type="sec"}\' tables.

![Risk of bias summary: review authors\' judgements about each risk of bias item for each included trial.](nCD000169-AFig-FIG03){#CD000169-fig-0003}

### Allocation {#CD000169-sec3-0020}

Six trials adequately described methods of sequence generation and allocation concealment to be considered at low risk of selection bias ([Fleming 1986 NGA](#CD000169-bbs2-0004){ref-type="ref-list"}; [Mbaye 2006 GMB](#CD000169-bbs2-0006){ref-type="ref-list"}; [Menendez 2008 MOZ](#CD000169-bbs2-0008){ref-type="ref-list"}; [Ndyomugyenyi 2011 UGA](#CD000169-bbs2-0012){ref-type="ref-list"}; [Shulman 1999 KEN](#CD000169-bbs2-0018){ref-type="ref-list"}; [Villegas 2007 THA](#CD000169-bbs2-0019){ref-type="ref-list"}). Four trials were quasi‐RCT and so at high risk of selection bias ([Cot 1992 BFA](#CD000169-bbs2-0002){ref-type="ref-list"}; [Cot 1995 CMR](#CD000169-bbs2-0003){ref-type="ref-list"}; [Morley 1964 NGA](#CD000169-bbs2-0009){ref-type="ref-list"}; [Parise 1998i KEN](#CD000169-bbs2-0017){ref-type="ref-list"}; [Parise 1998ii KEN](#CD000169-bbs2-0016){ref-type="ref-list"}), and in the remaining seven trials the risk was unclear.

### Blinding {#CD000169-sec3-0021}

Eleven trials used placebo tablets, identical in taste and appearance to the active drug, and were assessed as having low risk of performance bias.

Four trials explicitly stated that outcome assessors were blinded and were assessed as having low risk of detection bias ([Cot 1992 BFA](#CD000169-bbs2-0002){ref-type="ref-list"}; [Morley 1964 NGA](#CD000169-bbs2-0009){ref-type="ref-list"}; [Ndyomugyenyi 2011 UGA](#CD000169-bbs2-0012){ref-type="ref-list"}; [Villegas 2007 THA](#CD000169-bbs2-0019){ref-type="ref-list"}). In the remaining included trials the risk was unclear.

### Incomplete outcome data {#CD000169-sec3-0022}

Six trials had an attrition rate lower than 10% in both the intervention and control arm ([Menendez 2008 MOZ](#CD000169-bbs2-0008){ref-type="ref-list"}; [Morley 1964 NGA](#CD000169-bbs2-0009){ref-type="ref-list"}; [Nahlen 1989 NGA](#CD000169-bbs2-0010){ref-type="ref-list"}; [Ndyomugyenyi 2011 UGA](#CD000169-bbs2-0012){ref-type="ref-list"}; [Nosten 1994 THA](#CD000169-bbs2-0015){ref-type="ref-list"}; [Villegas 2007 THA](#CD000169-bbs2-0019){ref-type="ref-list"}). The remaining 11 trials were at high or unclear risk of attrition bias.

### Selective reporting {#CD000169-sec3-0023}

Birthweight data were not available in one trial, but we obtained this data from a subsequent review ([Njagi 2003i KEN](#CD000169-bbs2-0014){ref-type="ref-list"}; [Njagi 2003ii KEN](#CD000169-bbs2-0013){ref-type="ref-list"}; [ter Kuile 2007](#CD000169-bbs2-0064){ref-type="ref-list"}).

### Other potential sources of bias {#CD000169-sec3-0024}

In one trial, 18 participants were replaced by others after randomization ([Fleming 1986 NGA](#CD000169-bbs2-0004){ref-type="ref-list"}). We sought differences in baseline values with haemoglobin ([Analysis 1.4](#CD000169-fig-00104){ref-type="fig"}) and detected no obvious difference.

Effects of interventions {#CD000169-sec2-0010}
------------------------

See: [Table 1](#CD000169-tbl-0001){ref-type="table"}; [Table 2](#CD000169-tbl-0002){ref-type="table"}; [Table 3](#CD000169-tbl-0003){ref-type="table"}; [Table 4](#CD000169-tbl-0004){ref-type="table"}; [Table 5](#CD000169-tbl-0005){ref-type="table"}; [Table 6](#CD000169-tbl-0006){ref-type="table"}; [Table 7](#CD000169-tbl-0007){ref-type="table"}; [Table 8](#CD000169-tbl-0008){ref-type="table"}

### Comparison 1: Chemoprevention (any drug regimen) versus placebo/no chemoprevention {#CD000169-sec3-0025}

#### Chemoprevention for women in their first or second pregnancy {#CD000169-sec4-0005}

**Maternal outcomes** (see [Table 1](#CD000169-tbl-0001){ref-type="table"})

Only 15 maternal deaths were reported across all trials with no difference between groups (three trials, 2097 participants, [Analysis 1.1](#CD000169-fig-00101){ref-type="fig"}, *very low quality evidence*). Maternal death, even in these settings, is a relatively rare event occurring in less than five women per 1000 pregnancies. Consequently trials would need to enrol over 125,000 women to be adequately powered to detect or exclude effects as large as a 25% relative reduction (see [Table 11](#CD000169-tbl-0011){ref-type="table"}).

###### Optimal information size calculations: Chemoprevention versus placebo

  ------------------------ ------------------ ------------------------------------------------------ --------------------------------------------- -------------------------------
  **Outcome**              **Assumed risk**   **Source**                                             **Clinically important relative reduction**   **Sample size required^1,2^**
  Maternal mortality       350/100,000        [Analysis 1.1](#CD000169-fig-00101){ref-type="fig"}    25%                                           125228
  Severe anaemia           150/1000           [Analysis 1.2](#CD000169-fig-00102){ref-type="fig"}    25%                                           2540
  Anaemia                  650/1000           [Analysis 1.3](#CD000169-fig-00103){ref-type="fig"}    25%                                           284
  Malaria                  170/1000           [Analysis 1.5](#CD000169-fig-00105){ref-type="fig"}    25%                                           2194
  Parasitaemia             290/1000           [Analysis 1.6](#CD000169-fig-00106){ref-type="fig"}    25%                                           1124
  Spontaneous abortions    32/1000            [Analysis 1.9](#CD000169-fig-00109){ref-type="fig"}    25%                                           13348
  Still births             33/1000            [Analysis 1.10](#CD000169-fig-00110){ref-type="fig"}   25%                                           12932
  Neonatal deaths          37/1000            [Analysis 1.12](#CD000169-fig-00112){ref-type="fig"}   25%                                           11492
  Preterm birth            160/1000           [Analysis 1.13](#CD000169-fig-00113){ref-type="fig"}   25%                                           2356
  Low birthweight          150/1000           [Analysis 1.14](#CD000169-fig-00114){ref-type="fig"}   25%                                           2540
  Placental parasitaemia   300/1000           [Analysis 1.18](#CD000169-fig-00118){ref-type="fig"}   25%                                           1074
  ------------------------ ------------------ ------------------------------------------------------ --------------------------------------------- -------------------------------

^1^ All calculations are based on: 2‐sided tests, with a ratio of 1:1, power of 0.8, and confidence level of 0.05.  ^2^ All calculations were performed using: http://www.sealedenvelope.com/power/binary‐superiority

No trials reported on episodes of severe malaria, but three trials reported moderate to severe anaemia (defined as Hb \< 7/8 g/dL or PCV \< 21%). Overall, chemoprevention was associated with a 40% reduction in the risk of moderate to severe anaemia in the third trimester (RR 0.60, 95% CI 0.47 to 0.75; three trials, 2503 participants, [Analysis 1.2](#CD000169-fig-00102){ref-type="fig"}, *high quality evidence*). This effect was consistent despite variation in doses, and differences in the definition and timing of assessment for severe anaemia (I^2^ =0); [Parise 1998ii KEN](#CD000169-bbs2-0016){ref-type="ref-list"} recorded severe anaemia at delivery (after three doses of SP); [Shulman 1999 KEN](#CD000169-bbs2-0018){ref-type="ref-list"} at 34 weeks (after three doses of SP); [Menendez 2008 MOZ](#CD000169-bbs2-0008){ref-type="ref-list"} at delivery (after two doses of SP), and [Parise 1998i KEN](#CD000169-bbs2-0017){ref-type="ref-list"} at the beginning of the third trimester clinic visit (when the second dose of SP was due, and these women had only had one SP dose).

Chemoprevention was also associated with a reduction in the risk of any anaemia (defined as Hb \< 10/11/12 g/dL or PCV \< 33%/30%), although this reduction was generally of smaller magnitude (RR 0.83, 95% CI 0.74 to 0.93; five trials, 3662 participants, [Analysis 1.3](#CD000169-fig-00103){ref-type="fig"}, *high quality evidence*). In addition, measures of mean haemoglobin in the third trimester were higher in those receiving chemoprevention (MD 0.41 g/dL, 95% CI 0.29 to 0.54; five trials, 3363 participants, [Analysis 1.4](#CD000169-fig-00104){ref-type="fig"}).

Chemoprevention was associated with fewer episodes of presumed clinical malaria (history of fever), but this outcome was only reported in two small trials (RR 0.37, 95% CI 0.18 to 0.74; two trials, 307 participants, [Analysis 1.5](#CD000169-fig-00105){ref-type="fig"}, *low quality evidence*). Instead most trials reported antenatal parasitaemia, defined as either parasitaemia at delivery or parasitaemia at 34 to 36 weeks, with most trials showing benefits but wide variation in the size of the reduction (RR 0.39, 95% CI 0.26 to 0.58; eight trials, 3663 participants, I^2^ = 82; [Analysis 1.6](#CD000169-fig-00106){ref-type="fig"}, *high quality evidence*) This heterogeneity is probably not unexpected given the differences in chemoprevention regimens and malaria endemicity.

**Infant outcomes** (see [Table 2](#CD000169-tbl-0002){ref-type="table"}).

The trials and the meta‐analyses are underpowered to confidently detect or exclude effects on spontaneous abortion, perinatal deaths, or neonatal deaths (see [Table 11](#CD000169-tbl-0011){ref-type="table"}). The CIs range from important benefits to no evidence of any harm in four outcomes: spontaneous abortions (RR 0.65, 95% CI 0.41 to 1.02; five trials, 2876 participants, [Analysis 1.9](#CD000169-fig-00109){ref-type="fig"}, *low quality evidence*); perinatal deaths (RR 0.73, 95% CI 0.54 to 1.00; two trials, 1620 participants, [Analysis 1.11](#CD000169-fig-00111){ref-type="fig"}, *low quality evidence*); neonatal deaths (RR 0.62, 95% CI 0.37 to 1.05; two trials, 2156 participants, [Analysis 1.12](#CD000169-fig-00112){ref-type="fig"}, *low quality evidence*). The preterm births analysis was (RR 0.85, 95% CI 0.66 to 1.10; two trials, 1493 participants, [Analysis 1.13](#CD000169-fig-00113){ref-type="fig"}, *low quality evidence*).

Chemoprevention was associated with fewer low birthweight infants (RR 0.73, 95% CI 0.61 to 0.87; eight trials, 3619 participants, [Analysis 1.14](#CD000169-fig-00114){ref-type="fig"}, *moderate quality evidence*). and mean birthweight was higher with chemoprevention (MD 92.72 g, 95% CI 62.05 to 123.39; nine trials, 3936 participants, [Analysis 1.15](#CD000169-fig-00115){ref-type="fig"}, *moderate quality evidence*).

One very small trial reported no difference in the prevalence of cord blood anaemia (64 participants, [Analysis 1.16](#CD000169-fig-00116){ref-type="fig"}), and a lower cord blood haemoglobin in babies born to women receiving chemoprevention (MD ‐1.80 g/dL, 95% CI ‐3.46 to ‐0.14; one trial, 64 participants, [Analysis 1.17](#CD000169-fig-00117){ref-type="fig"}, *very low quality evidence*).

Chemoprevention resulted in fewer cases of placental parasitaemia (RR 0.54, 95% CI 0.43 to 0.69; seven trials, 2830 participants, [Analysis 1.17](#CD000169-fig-00117){ref-type="fig"}, *high quality evidence*). Only one trial examined cord blood parasitaemia, but there were too few events to be confident of the result (RR 0.47, 95% CI 0.22 to 1.01; one trial, 1335 participants, [Analysis 1.19](#CD000169-fig-00119){ref-type="fig"}). The children born to mothers receiving monthly SP had reduced cord parasitaemia, whereas those born to mothers receiving two doses of SP did not ([Parise 1998i KEN](#CD000169-bbs2-0017){ref-type="ref-list"}).

#### Chemoprevention for multigravidae {#CD000169-sec4-0006}

**Maternal outcomes** (see [Table 3](#CD000169-tbl-0003){ref-type="table"}).

Four trials provided data on multigravidae women. Only one trial assessed mortality with six deaths in the chemoprevention group and four in the control group (RR 1.47, 95% CI 0.42 to 5.21; one trial, 2239 participants, [Analysis 1.1](#CD000169-fig-00101){ref-type="fig"}, *very low quality evidence*).

No trials reported episodes of severe malaria, but two reported severe anaemia. In one trial more women had severe anaemia in the chemoprevention group (RR 1.20, 95% CI 0.91 to 1.57; one trial, 1954 participants), and the second trial had few events and consequently very wide CIs (RR 0.41, 95% CI 0.08 to 2.09; one trial, 728 participants). The 95% CIs of the overall meta‐analysis does not exclude effects as large as those seen in women in their first or second pregnancy but this is probably unlikely (RR 0.96, 95% CI 0.41 to 2.25; two trials, 2682 participants, [Analysis 1.2](#CD000169-fig-00102){ref-type="fig"}).

No trials reported the risk of mild anaemia, but two trials reported mean haemoglobin at delivery without clinically important differences between groups (MD 0.01 g/dL, 95% CI ‐0.23 to 0.24; two trials, 676 participants, [Analysis 1.4](#CD000169-fig-00104){ref-type="fig"}).

No trial measured malaria or febrile episodes in the mother. Four trials reported antenatal parasitaemia, and all four trials report large effects of a similar magnitude to those seen in women in their first or second pregnancy (RR 0.38, 95% CI 0.28 to 0.50; four trials, 3022 participants, [Analysis 1.6](#CD000169-fig-00106){ref-type="fig"}, *high quality evidence*).

**Infant outcomes** (see [Table 4](#CD000169-tbl-0004){ref-type="table"}).

Two trials included information on infant outcomes after chemoprevention given to multigravid women.

Spontaneous abortions, stillbirths and perinatal deaths were not reported. One trial reported deaths in the first six weeks of life with slightly higher deaths following chemoprevention, but with wide CIs including the possibility of no difference between groups (RR 1.46, 95% CI 0.90 to 2.38; one trial, 2017 participants, [Analysis 1.12](#CD000169-fig-00112){ref-type="fig"}).

No trials reported mean birthweight in infants born to multigravid women, but three reported the risk of low birthweight. The trend is in favour of chemoprevention but neither the trials, or the meta‐analysis reached standard levels of statistical significance (RR 0.86, 95% CI 0.64 to 1.17; three trials, 2743 participants, [Analysis 1.14](#CD000169-fig-00114){ref-type="fig"}, *very low quality evidence).*

No trials reported measures of placental parasitaemia, cord blood parasitaemia, or cord blood haemoglobin.

#### Chemoprevention for all women {#CD000169-sec4-0007}

To evaluate the population effects of a policy of chemoprevention for all pregnant women, regardless of parity, this third analysis includes all trials which recruited women of any parity. Some of these presented results stratified by parity and were included in the analyses above, but a few additional trials did not provide their outcome data stratified by parity.

**Maternal outcomes** (see [Table 5](#CD000169-tbl-0005){ref-type="table"}).

For maternal mortality, only nine maternal deaths were recorded in trials recruiting women of all parities; 4/3019 with chemoprevention and 5/3007 without (four trials, 6026 participants, [Analysis 1.1](#CD000169-fig-00101){ref-type="fig"}, *low quality evidence*).

For severe anaemia in the mother, there were very few events recorded in the two trials but the risk was lower with chemoprevention (RR 0.19, 95% CI 0.05 to 0.75; two trials, 1327 participants, [Analysis 1.2](#CD000169-fig-00102){ref-type="fig"}, *low quality evidence*). For any anaemia, no population differences were demonstrated (RR 1.03, 95% CI 0.87 to 1.23; three trials, 3027 participants, [Analysis 1.3](#CD000169-fig-00103){ref-type="fig"}, *moderate quality evidence*). Three trials reported mean haemoglobin, with only one very small trial from the early 1990s finding benefit with chemoprevention (three trials, 2223 participants, [Analysis 1.4](#CD000169-fig-00104){ref-type="fig"}).

Clinical malaria (or history of fever) was reported in four of the trials across all parity groups. The older, and smaller trials, suggested a population benefit on clinical malaria but this was not seen in the two recent and much larger trials using two doses of SP (four trials, 3455 participants, [Analysis 1.5](#CD000169-fig-00105){ref-type="fig"}, *low quality evidence*).

For parasitaemia at delivery, there was considerable heterogeneity between trials (I^2^ = 79%). Of the two most recent trials, both large, and both administering two doses of SP, one trial from Mozambique demonstrated a benefit with chemoprevention and one from Uganda did not (five trials, 3961 participants, [Analysis 1.6](#CD000169-fig-00106){ref-type="fig"}, *low quality evidence*).

**Infant outcomes** (see [Table 6](#CD000169-tbl-0006){ref-type="table"}).

In trials recruiting women of all parities, no differences were demonstrated for spontaneous abortions (three trials, 5767 participants, [Analysis 1.9](#CD000169-fig-00109){ref-type="fig"}, *low quality evidence*), stillbirths (five trials, 7130 participants, [Analysis 1.10](#CD000169-fig-00110){ref-type="fig"}, *moderate quality evidence*), perinatal deaths (four trials, 5216 participants, [Analysis 1.11](#CD000169-fig-00111){ref-type="fig"}, *moderate quality evidence*), or neonatal and infant deaths (five trials, 6313 participants, [Analysis 1.12](#CD000169-fig-00112){ref-type="fig"}, *moderate quality evidence*). We also pooled across all trials for these outcomes (including those which only recruited women in their first or second pregnancies), and no differences were demonstrated.

Population benefits for the infants were not demonstrated for pre‐term birth (two trials, 1174 participants, [Analysis 1.13](#CD000169-fig-00113){ref-type="fig"}, *low quality evidence*), low birthweight (four trials, 3644 participants, [Analysis 1.14](#CD000169-fig-00114){ref-type="fig"}, *low quality evidence*), or mean birthweight (five trials, 6007 participants, [Analysis 1.15](#CD000169-fig-00115){ref-type="fig"}, *moderate quality evidence*).

The effects of chemoprevention on placental parasitaemia were mixed (I^2^ = 94%), with large effects in two older trials administering monthly pyrimethamine or weekly chloroquine, and no effect demonstrated in the two more recent trials administering two doses of SP (four trials, 3200 participants, [Analysis 1.18](#CD000169-fig-00118){ref-type="fig"}, *low quality evidence*).

One trial in Mozambique found a large effect in reducing the risk of cord blood anaemia (RR 0.49, 95% CI 0.30 to 0.80; one trial, 870 participants, [Analysis 1.16](#CD000169-fig-00116){ref-type="fig"}), and increase in mean cord PCV (MD 1.01%, 95% CI 0.05 to 1.97; one trial, 990 participants, [Analysis 1.17](#CD000169-fig-00117){ref-type="fig"}).

#### Adverse effects {#CD000169-sec4-0008}

We aggregated adverse effects across all parity groups. Reporting of adverse effects was generally poor. Only five trials specifically stated that no adverse effects attributable to the drugs were observed in the mothers, and the rest either did not report adverse effects or the information was unclear. Four trials reported adverse events following SP ([Analysis 1.7](#CD000169-fig-00107){ref-type="fig"}), and one trial following mefloquine ([Analysis 1.8](#CD000169-fig-00108){ref-type="fig"}). No differences were seen between the treatment and control groups.

Again, reporting of adverse events in the neonate was generally poor. Episodes of neonatal kernicterus were reported in two trials, and congenital anomalies in two trials, with no differences detected ([Analysis 1.20](#CD000169-fig-00120){ref-type="fig"}).

#### Comparison 2. SP IPT chemoprevention for women in their first or second pregnancy {#CD000169-sec4-0009}

The above analysis examines the effects of drugs known to be effective in preventing malaria at the particular time the trials were carried out. As the WHO currently recommends intermittent dosing with SP, we performed an additional analysis to provide the effect estimates for SP compared to no drug or placebo. The analysis is exactly the same as comparison one, but we included only the six SP trials. These trials administered SP in two doses ([Parise 1998i KEN](#CD000169-bbs2-0017){ref-type="ref-list"}; [Njagi 2003i KEN](#CD000169-bbs2-0014){ref-type="ref-list"}; [Njagi 2003ii KEN](#CD000169-bbs2-0013){ref-type="ref-list"}; [Challis 2004 MOZ](#CD000169-bbs2-0001){ref-type="ref-list"}; [Menendez 2008 MOZ](#CD000169-bbs2-0008){ref-type="ref-list"}; [Ndyomugyenyi 2011 UGA](#CD000169-bbs2-0012){ref-type="ref-list"}), three doses ([Shulman 1999 KEN](#CD000169-bbs2-0018){ref-type="ref-list"}), or monthly ([Parise 1998ii KEN](#CD000169-bbs2-0016){ref-type="ref-list"}).

**Maternal outcomes** (see [Table 7](#CD000169-tbl-0007){ref-type="table"}).

For maternal death, no effect was demonstrated but the analysis is underpowered ([Analysis 2.1](#CD000169-fig-00201){ref-type="fig"}).

For women of low parity, restricting the analysis to trials of SP did not substantially change the estimates of benefit on severe anaemia (RR 0.60, 95% CI 0.47 to 0.75; three trials, 2503 participants, [Analysis 2.2](#CD000169-fig-00202){ref-type="fig"}, *high quality evidence*), mild anaemia (RR 0.88, 95% CI 0.88 to 0.96; three trials, 3219 participants, [Analysis 2.3](#CD000169-fig-00203){ref-type="fig"}, *moderate quality evidence*), or mean haemoglobin (MD 0.41 g higher, 95% CI 0.27 to 0.54; three trials, 2995 participants, [Analysis 2.4](#CD000169-fig-00204){ref-type="fig"}).

Similarly, the reduction in antenatal parasitaemia is consistent with the overall effect from trials of any chemoprevention (RR 0.38, 95% 0.24 to 0.59; four trials, 2832 participants, [Analysis 2.5](#CD000169-fig-00205){ref-type="fig"}, *high quality evidence*), but there is insufficient data to draw conclusions on clinical malaria (RR 0.24, 95% CI 0.05 to 1.12; one trial, 174 participants, *very low quality evidence* ([Analysis 2.6](#CD000169-fig-00206){ref-type="fig"}).

**Infant outcomes** (see [Table 8](#CD000169-tbl-0008){ref-type="table"}).

The trials and the meta‐analyses are underpowered to confidently detect or exclude effects on spontaneous abortion, stillbirth, perinatal deaths, or neonatal deaths, but restricting the analysis to trials of SP did not substantially change the estimates of effect (see [Analysis 2.7](#CD000169-fig-00207){ref-type="fig"}; [Analysis 2.8](#CD000169-fig-00208){ref-type="fig"}; [Analysis 2.9](#CD000169-fig-00209){ref-type="fig"}; [Analysis 2.10](#CD000169-fig-00210){ref-type="fig"}; *low quality evidence*). The trend is towards a reduction in pre‐term birth but the 95% CI is wide and includes the possibility of no effect (RR 0.85, 95% CI 0.66 to 1.10; two trials, 1493 participants, [Analysis 2.11](#CD000169-fig-00211){ref-type="fig"}, *low quality evidence*).

Overall, chemoprevention with SP reduced the incidence of low birthweight but this effect seems to be reducing over time, with large effects in the older trials and no effect seen in the more recent trials using two doses of SP (four trials, 3043 participants, [Analysis 2.12](#CD000169-fig-00212){ref-type="fig"}, *moderate quality evidence*). However, mean birthweight was higher with SP, and this effect was still present in the most recent trials (MD 105.5 g, 95% CI 68.02 to 142.9, four trials, 2693 participants, [Analysis 2.13](#CD000169-fig-00213){ref-type="fig"}, *moderate quality evidence*).

Chemoprevention with SP reduced placental parasitaemia (RR 0.45, 95% CI 0.33 to 0.61; three trials, 1633 participants, [Analysis 2.14](#CD000169-fig-00214){ref-type="fig"}, *high quality evidence*) but only one trial of SP reported cord parasitaemia (RR 0.47, 95% CI 0.22 to 1.01; one trial, 1335 participants, [Analysis 2.15](#CD000169-fig-00215){ref-type="fig"}).

##### Adverse effects {#CD000169-sec5-0001}

No effects were detected with icterus (two trials, 2233 participants, [Analysis 2.16](#CD000169-fig-00216){ref-type="fig"}) or congenital abnormalities (one trial, 1017 participants, [Analysis 2.16](#CD000169-fig-00216){ref-type="fig"}).

#### Comparison 3. Chemoprevention for *P. vivax* {#CD000169-sec4-0010}

Only one trial reported on chemoprevention for *P. vivax*, conducted in Thailand with weekly prophylaxis with chloroquine. It was rated at low risk of bias on all criteria. It seemed to prevent completely all episodes of *P. vivax* malaria (RR 0.01, 95% CI 0.00 to 0.20; 942 participants, see [Table 12](#CD000169-tbl-0012){ref-type="table"}), but had no effect on maternal anaemia, low birthweight, or mean birthweight. It was underpowered to assess effects on mortality.

###### Chloroquine versus placebo (effect on *P. vivax* malaria)

  ---------------------------------- ------------ ------------------ ------------------------------------------ --------------------------------------------------------------------------
  **Outcomes**                       **Trials**   **Participants**   **Effect estimate**                        **Comment**

  Death (mother)                     1            951                Risk ratio 0.34 (0.01, 8.28)               ‐

  Severe anaemia                     1            ‐                  ‐                                          Not reported

  Anaemia                            1            951                Risk ratio 1.00 (0.92, 1.08)               Defined as PCV \< 30%

  Clinical malaria                   1            ‐                  ‐                                          Not reported

  *P. vivax* parasitaemia            1            942                Risk ratio 0.01 (0.00, 0.20)               History of antenatal parasitaemia. Nine women censored (they had *P.*\
                                                                                                                *falciparum* infection prior to their first *P. vivax* episode)

  Adverse effects with chloroquine   1            951                Risk ratio 2.03 (0.18, 22.31)              The 5 most commonly reported adverse events were headache, anorexia,\
                                                                                                                sleep disorder, dizziness and weakness. CQ group: drug suspended in two\
                                                                                                                cases (1 ‐ constipation,1‐ nausea)\
                                                                                                                One woman in the placebo group was complaining of visual problems

  Spontaneous abortion               1            951                Risk ratio 0.71 (0.36, 1.39)               ‐

  Stillbirth                         1            865                Risk ratio 0.24 (0.03, 2.17)               ‐

  Perinatal deaths                   1            ‐                  ‐                                          Not reported

  Neonatal and infant mortality      1            ‐                  ‐                                          Not reported

  Preterm birth (All)                1            733                Risk ratio 0.93 (0.46, 1.85)               ‐

  Preterm birth (Para 0)             1            141                Risk ratio 2.41 (0.63, 9.24)               ‐

  Preterm birth (Para 2+)            1            592                Risk ratio 0.62 (0.26, 1.46)               ‐

  Low birthweight (All)              1            733                Risk ratio 1.02 (0.71, 1.46)               ‐

  Low birthweight (Para 0)           1            141                Risk ratio 1.20 (0.65, 2.21)               ‐

  Low birthweight (Para 2+)          1            592                Risk ratio 0.94 (0.60, 1.47)               ‐

  Mean birthweight (All)             1            733                Mean difference ‐8.20 (‐73.41, 57.02)      ‐

  Mean birthweight (Para 0)          1            141                Mean difference ‐36.00 (‐188.73, 116.73)   Mean (SD) 2741 ± 481 versus 2777 ± 435 in the CQ versus placebo group

  Mean birthweight (Para 2+)         1            592                Mean difference ‐2.00 (‐74.12, 70.12)      Mean (SD) 2954 ± 423 versus 2956 ± 471 in the CQ versus placebo group

  Placental malaria                  1            ‐                  ‐                                          Not reported

  Cord blood haemoglobin             1            ‐                  ‐                                          Not reported

  Cord blood parasitaemia            1            ‐                  ‐                                          Not reported

  Adverse effects (baby)             1            864                Risk ratio 1.22 (0.33, 4.50)               Congenital anomalies: Amniotic banding, brachydactyly; anophthalmia,\
                                                                                                                Down\'s syndrome,; amniotic banding,\
                                                                                                                absent digit toes; two cleft lip, one cleft palate in the placebo group.
  ---------------------------------- ------------ ------------------ ------------------------------------------ --------------------------------------------------------------------------

Discussion {#CD000169-sec1-0006}
==========

Summary of main results {#CD000169-sec2-0011}
-----------------------

We included 17 trials, enrolling 14,481 pregnant women, in this Cochrane Review.

For women in their first or second pregnancy, malaria chemoprevention reduces the risk of moderate to severe anaemia by around 40% (*high quality evidence*), and the risk of any anaemia by around 17% (*high quality evidence*). Malaria chemoprevention reduces the risk of antenatal parasitaemia by around 61% (*high quality evidence*), and two trials reported a reduction in febrile illness (*low quality evidence*). There were only 16 maternal deaths and these trials were underpowered to detect an effect on maternal mortality (*very low quality evidence*).

For infants of women in their first and second pregnancies, malaria chemoprevention probably increases mean birthweight by around 93 g (*moderate quality evidence*), reduces low birthweight by around 27% (*moderate quality evidence*), and reduces placental parasitaemia by around 46% (*high quality evidence*). Fewer trials evaluated spontaneous abortions, still births, perinatal deaths, or neonatal deaths, and these analyses were underpowered to detect clinically important differences.

In multigravid women, chemoprevention has similar effects on antenatal parasitaemia (*high quality evidence*) but there are too few trials to evaluate effects on other outcomes.

In trials giving chemoprevention to all pregnant women irrespective of parity, the average effects of chemoprevention measured in all women indicated it may prevent severe anaemia (*low quality evidence),* but consistent benefits have not been shown for other outcomes.

In an analysis confined only to intermittent preventive therapy with SP, the estimates of effect and the quality of the evidence were similar.

A summary of a single trial in Thailand of prophylaxis against vivax showed chloroquine prevented vivax infection (RR 0.01, 95% CI 0.00 to 0.20; 942 participants).

Overall completeness and applicability of evidence {#CD000169-sec2-0012}
--------------------------------------------------

Trials were almost exclusively from Africa and published between 1964 and 2011. These trials, from a variety of settings and using varied chemoprevention regimens, found fairly consistent clinically important benefits for low parity women and their infants.

However, it is possible that with the introduction of ACTs, declining malaria transmission in some areas of Africa, and increasing quality of antenatal services, that the attributable fraction of malaria towards maternal anaemia and low birthweight has been reduced and the large effects seen in these trials may be attenuated by less malaria and better individualized care of women during pregnancy.

Quality of the evidence {#CD000169-sec2-0013}
-----------------------

The evidence for effects on maternal, foetal and neonatal mortality is generally considered of low or very low quality because the trials and the meta‐analysis remain significantly underpowered to confidently prove or exclude clinically important effects.

For women of low parity, we considered the evidence of clinically important effects on anaemia and antenatal parasitaemia to be of high quality, meaning we can have confidence in these results. For the infants of women of low parity, we considered the effects on birthweight to only be of moderate quality because of the high risk of bias of most of the older trials. This means we can have only moderate confidence in the magnitude of these effects.

Trials did not describe the routine health services available to detect and treat malaria infection in both intervention and control arms, but many trials were done some years ago in areas with very basic curative health services available. However, in the future with declining levels of malaria the individual management of illness and malaria at clinic may become an important option to control malaria in pregnancy.

Potential biases in the review process {#CD000169-sec2-0014}
--------------------------------------

It seems unlikely that we have missed any trials. As trials did not systematically document adverse effects, it is likely that these have been underestimated in this review.

Agreements and disagreements with other studies or reviews {#CD000169-sec2-0015}
----------------------------------------------------------

The findings of this Cochrane Review are consistent with previous editions ([Garner 2006](#CD000169-bbs2-0073){ref-type="ref-list"}; [ter Kuile 2007](#CD000169-bbs2-0064){ref-type="ref-list"}). The findings are also consistent with the findings of a review comparing observational and randomized evidence ([McClure 2013](#CD000169-bbs2-0058){ref-type="ref-list"}). [McClure 2013](#CD000169-bbs2-0058){ref-type="ref-list"} points out that the fairly modest effects seen in RCTs, where delivery of care is often strengthened and adherence assured, were attenuated in the observational studies where, the authors surmise, delivery of the intervention and adherence to it may be attenuated. However, this contrasts with a study estimating the effects of IPT with SP on low birthweight and neonatal mortality from survey data: the trial estimates are remarkably similar to the results observed with IPT with SP from the trial data reported in this and previous analysis ([Eisele 2012](#CD000169-bbs2-0053){ref-type="ref-list"}; [ter Kuile 2007](#CD000169-bbs2-0064){ref-type="ref-list"}).

Authors\' conclusions {#CD000169-sec1-0007}
=====================

Implications for practiceRoutine chemoprevention to prevent malaria and its consequences has been extensively tested in RCTs, with clinically important benefits on anaemia and parasitaemia in the mother, and on birthweight in infants.The data also assists in showing the potential attribution of malaria towards key endpoints, and what can be achieved by successful prevention to assist in modelling studies examining the impact of malaria on pregnancy.

Implications for researchIdentifying current effective chemoprevention regimens remains a challenge, especially with the spread of drug‐resistant malaria, in particular against SP which is the only antimalarial currently recommended for IPT in pregnant women. There is justification for assessing the safety and efficacy of effects of alternative drugs that can replace SP in areas with high SP resistance, or alternative strategies that could replace IPT during pregnancy, such as intermittent screen and treat (IST) approaches that focus on prompt accessible treatment for anaemia and asymptomatic parasitaemia ([Tagbor 2010](#CD000169-bbs2-0047){ref-type="ref-list"}).All new trials should systematically and carefully collect adverse effects of regimens.The data on the longer term impact on infants is poor and needs further study: currently the evidence mainly relates to effects on clinically important outcomes, such as preterm birth and birthweight.There is a dearth of data from endemic areas outside of Africa, such as Asia and Latin America.

What\'s new {#CD000169-sec1-0013}
===========

**DateEventDescription**29 September 2014New citation required but conclusions have not changedWe repeated all searches. Trial inclusion criteria, data extraction, risk of bias assessment, and data entry were all done afresh. We additionally carried out GRADE analysis and a sensitivity analysis of IPT. Contributions of individuals are outlined in section \'Contributions of authors\'.29 September 2014New search has been performedReview updated.

History {#CD000169-sec1-0014}
=======

Protocol first published: Issue 1, 1995  Review first published: Issue 1, 1995

**DateEventDescription**16 September 2008AmendedConverted to new review format with minor editing.20 August 2006Amended2006, Issue 4: added [Challis 2004 MOZ](#CD000169-bbs2-0001){ref-type="ref-list"} and Kayentao 2005 MLIa; meta‐analysis stratified by prophylaxis and intermittent preventive treatment; review title shortened.20 November 2002Amended2003, Issue 1: Review overhauled to reflect current methods; title was altered to \"Drugs for preventing malaria‐related illness in pregnant women and death in the newborn\" (from \"Prevention versus treatment for malaria in pregnant women\"); we excluded mosquito nets as these are now covered by Gamble 2006; primary outcome measures were adjusted following feedback from readers; methodological quality of trials reassessed; [Martin 1982](#CD000169-bbs2-0034){ref-type="ref-list"} trial previously included, but now excluded because it is not randomized.28 February 2001AmendedPrimary outcome measures defined; Parise 1998 trial added.

We thank Metin Gulmezoglu, an author on a previous version of this Cochrane Review. Others contributed to earlier published versions of this review and are acknowledged there. In this version, we thank Mari Luntamo and her team for contributing unpublished data and stratified analysis by HIV status of the mother, not included in their original published paper.

This document is an output from a project funded by the UK Department for International Development (DFID) for the benefit of developing countries. The views expressed are not necessarily those of DFID.

The editorial base for the Cochrane Infectious Diseases Group is funded by UK Aid from the UK Government for the benefit of developing countries.

**Search setCIDG SR^a^CENTRALMEDLINE^b^EMBASE^b^LILACS^b^**1malariaMALARIAMALARIAMALARIAmalaria2pregnan\*malariamalariamalariapregnan\*31 and 21 or 21 or 21 or 21 and 24---PREGNANCYPREGNANCYPREGNANCY---5---pregnan\*pregnan\*pregnan\$---6---4 or 54 or 54 or 5---7---3 and 63 and 63 and 6---8------Limit 7 to humanLimit 7 to human---

^a^Cochrane Infectious Diseases Group Specialized Register.  ^b^Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration ([Higgins 2005](#CD000169-bbs2-0055){ref-type="ref-list"}); upper case: MeSH or EMTREE heading; lower case: free text term.

**Chemoprevention regimenTrialsDrugDoseFrequency**Chloroquine300 mgWeekly[Cot 1992 BFA](#CD000169-bbs2-0002){ref-type="ref-list"}; [Cot 1995 CMR](#CD000169-bbs2-0003){ref-type="ref-list"}; [Ndyomugyenyi 2000 UGA](#CD000169-bbs2-0011){ref-type="ref-list"}; [Villegas 2007 THA](#CD000169-bbs2-0019){ref-type="ref-list"}Pyrimethamine100 mgMonthly[Morley 1964 NGA](#CD000169-bbs2-0009){ref-type="ref-list"}25 mgWeekly[Nahlen 1989 NGA](#CD000169-bbs2-0010){ref-type="ref-list"}Proguanil100 mgDaily[Fleming 1986 NGA](#CD000169-bbs2-0004){ref-type="ref-list"}Pyrimethamine‐dapsone25 mg/100 mgEvery two weeks[Greenwood 1989 GMB](#CD000169-bbs2-0005){ref-type="ref-list"}12.5 mg/100 mgWeekly[Menendez 1994 GMB](#CD000169-bbs2-0007){ref-type="ref-list"}Sulfadoxine‐pyrimethamine1500 mg/75 mgOne to two doses[Shulman 1999 KEN](#CD000169-bbs2-0018){ref-type="ref-list"}Two doses[Challis 2004 MOZ](#CD000169-bbs2-0001){ref-type="ref-list"}; [Menendez 2008 MOZ](#CD000169-bbs2-0008){ref-type="ref-list"}; [Njagi 2003i KEN](#CD000169-bbs2-0014){ref-type="ref-list"}; [Parise 1998i KEN](#CD000169-bbs2-0017){ref-type="ref-list"}Up to four doses[Mbaye 2006 GMB](#CD000169-bbs2-0006){ref-type="ref-list"}Monthly[Parise 1998ii KEN](#CD000169-bbs2-0016){ref-type="ref-list"}Mefloquine500 mg loading dose, 250 mg weekly for 4 weeks, 125 mg weekly until deliveryWeekly[Nosten 1994 THA](#CD000169-bbs2-0015){ref-type="ref-list"}

**No. of pregnanciesTrials**number of trialsAll women[Morley 1964 NGA](#CD000169-bbs2-0009){ref-type="ref-list"}; [Nahlen 1989 NGA](#CD000169-bbs2-0010){ref-type="ref-list"}; [Cot 1992 BFA](#CD000169-bbs2-0002){ref-type="ref-list"}; [Nosten 1994 THA](#CD000169-bbs2-0015){ref-type="ref-list"}; [Greenwood 1989 GMB](#CD000169-bbs2-0005){ref-type="ref-list"}; [Villegas 2007 THA](#CD000169-bbs2-0019){ref-type="ref-list"}; [Menendez 2008 MOZ](#CD000169-bbs2-0008){ref-type="ref-list"}; [Ndyomugyenyi 2011 UGA](#CD000169-bbs2-0012){ref-type="ref-list"};8First pregnancy[Fleming 1986 NGA](#CD000169-bbs2-0004){ref-type="ref-list"}; [Menendez 1994 GMB](#CD000169-bbs2-0007){ref-type="ref-list"}; [Cot 1995 CMR](#CD000169-bbs2-0003){ref-type="ref-list"}; [Shulman 1999 KEN](#CD000169-bbs2-0018){ref-type="ref-list"}; [Ndyomugyenyi 2000 UGA](#CD000169-bbs2-0011){ref-type="ref-list"}; [Challis 2004 MOZ](#CD000169-bbs2-0001){ref-type="ref-list"}6First or second pregnancy[Parise 1998i KEN](#CD000169-bbs2-0017){ref-type="ref-list"}; [Njagi 2003ii KEN](#CD000169-bbs2-0013){ref-type="ref-list"}2Only multiparous women[Mbaye 2006 GMB](#CD000169-bbs2-0006){ref-type="ref-list"}1

[Nahlen 1989 NGA](#CD000169-bbs2-0010){ref-type="ref-list"}; [Greenwood 1989 GMB](#CD000169-bbs2-0005){ref-type="ref-list"}; [Menendez 2008 MOZ](#CD000169-bbs2-0008){ref-type="ref-list"} all provided data disaggregated by parity.

**TrialWomenNewbornsOutcomen/N^a^% in analysisOutcomen/N^a^% in analysis**[Challis 2004 MOZ](#CD000169-bbs2-0001){ref-type="ref-list"}Parasitaemia411/60069Low birthweight403/60067[Cot 1992 BFA](#CD000169-bbs2-0002){ref-type="ref-list"}Placental malaria904/146462Birthweight1148/1148100[Cot 1995 CMR](#CD000169-bbs2-0003){ref-type="ref-list"}Placental malaria120/26657Birthweight209/26679[Fleming 1986 NGA](#CD000169-bbs2-0004){ref-type="ref-list"}Haemoglobin107/20045Perinatal death152/20076[Greenwood 1989 GMB](#CD000169-bbs2-0005){ref-type="ref-list"}Parasitaemia257/104924Birthweight877/103485[Menendez 1994 GMB](#CD000169-bbs2-0007){ref-type="ref-list"}Placental malaria116/23050Birthweight182/20390[Morley 1964 NGA](#CD000169-bbs2-0009){ref-type="ref-list"}Antenatal parasitaemia227/42953Birthweight429/429100[Nahlen 1989 NGA](#CD000169-bbs2-0010){ref-type="ref-list"}Parasitaemia71/71100---------[Ndyomugyenyi 2000 UGA](#CD000169-bbs2-0011){ref-type="ref-list"}Anaemia510/86059Congenital malaria337/51066[Nosten 1994 THA](#CD000169-bbs2-0015){ref-type="ref-list"}Parasitaemia399/399100Birthweight290/290100[Parise 1998i KEN](#CD000169-bbs2-0017){ref-type="ref-list"}, [Parise 1998ii KEN](#CD000169-bbs2-0016){ref-type="ref-list"}Haemoglobin1378/207766---------[Shulman 1999 KEN](#CD000169-bbs2-0018){ref-type="ref-list"}Severe anaemia1132/126490---------

^a^Number analysed/number randomized.

###### Preventive antimalarials versus placebo/no intervention

  Outcome or subgroup title                                                  No. of studies   No. of participants   Statistical method                    Effect size
  -------------------------------------------------------------------------- ---------------- --------------------- ------------------------------------- -------------------------
  [1 Death (mother)](#CD000169-fig-00101){ref-type="fig"}                    9                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  1.1 Para 0‐1                                                               4                2097                  Risk Ratio (M‐H, Fixed, 95% CI)       1.15 \[0.44, 3.06\]
  1.2 Multigravidae                                                          1                2239                  Risk Ratio (M‐H, Fixed, 95% CI)       1.47 \[0.42, 5.21\]
  1.3 All women                                                              4                6026                  Risk Ratio (M‐H, Fixed, 95% CI)       0.84 \[0.25, 2.74\]
  [2 Severe anaemia (mother)](#CD000169-fig-00102){ref-type="fig"}           6                                      Risk Ratio (M‐H, Random, 95% CI)      Subtotals only
  2.1 Para 0‐1                                                               4                2503                  Risk Ratio (M‐H, Random, 95% CI)      0.60 \[0.47, 0.75\]
  2.2 Multigravidae                                                          2                2682                  Risk Ratio (M‐H, Random, 95% CI)      0.96 \[0.41, 2.25\]
  2.3 All women                                                              2                1327                  Risk Ratio (M‐H, Random, 95% CI)      0.19 \[0.05, 0.75\]
  [3 Anaemia (mother)](#CD000169-fig-00103){ref-type="fig"}                  10                                     Risk Ratio (M‐H, Random, 95% CI)      Subtotals only
  3.1 Para 0‐1                                                               7                3662                  Risk Ratio (M‐H, Random, 95% CI)      0.83 \[0.74, 0.93\]
  3.2 All women                                                              3                3027                  Risk Ratio (M‐H, Random, 95% CI)      1.03 \[0.87, 1.23\]
  [4 Mean haemoglobin (g/dL)](#CD000169-fig-00104){ref-type="fig"}           10                                     Mean Difference (IV, Fixed, 95% CI)   Subtotals only
  4.1 Baseline Hb                                                            5                3004                  Mean Difference (IV, Fixed, 95% CI)   0.04 \[‐0.10, 0.17\]
  4.2 Para 0‐1                                                               7                3363                  Mean Difference (IV, Fixed, 95% CI)   0.41 \[0.29, 0.54\]
  4.3 Multigravidae                                                          2                676                   Mean Difference (IV, Fixed, 95% CI)   0.01 \[‐0.23, 0.24\]
  4.4 All women                                                              3                2223                  Mean Difference (IV, Fixed, 95% CI)   0.13 \[0.00, 0.25\]
  [5 Clinical malaria (mother)](#CD000169-fig-00105){ref-type="fig"}         6                                      Risk Ratio (M‐H, Random, 95% CI)      Subtotals only
  5.1 Para 0‐1                                                               2                307                   Risk Ratio (M‐H, Random, 95% CI)      0.37 \[0.18, 0.74\]
  5.2 All women                                                              4                3455                  Risk Ratio (M‐H, Random, 95% CI)      0.37 \[0.11, 1.23\]
  [6 Parasitaemia (mother)](#CD000169-fig-00106){ref-type="fig"}             13                                     Risk Ratio (M‐H, Random, 95% CI)      Subtotals only
  6.1 Para 0‐1                                                               10               3663                  Risk Ratio (M‐H, Random, 95% CI)      0.39 \[0.26, 0.58\]
  6.2 Multigravidae                                                          4                3022                  Risk Ratio (M‐H, Random, 95% CI)      0.38 \[0.28, 0.50\]
  6.3 All women                                                              5                3961                  Risk Ratio (M‐H, Random, 95% CI)      0.70 \[0.44, 1.13\]
  [7 Adverse effects with SP](#CD000169-fig-00107){ref-type="fig"}           5                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  7.1 Skin reactions                                                         2                1472                  Risk Ratio (M‐H, Fixed, 95% CI)       0.85 \[0.27, 2.65\]
  7.2 Nausea and vomiting                                                    2                1472                  Risk Ratio (M‐H, Fixed, 95% CI)       1.69 \[0.22, 12.81\]
  7.3 Any other adverse effects                                              3                2599                  Risk Ratio (M‐H, Fixed, 95% CI)       0.72 \[0.38, 1.36\]
  [8 Adverse effects with mefloquine](#CD000169-fig-00108){ref-type="fig"}   1                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  8.1 Dizziness                                                              1                107                   Risk Ratio (M‐H, Fixed, 95% CI)       1.6 \[0.90, 2.83\]
  8.2 Vertigo                                                                1                339                   Risk Ratio (M‐H, Fixed, 95% CI)       1.02 \[0.81, 1.28\]
  8.3 Vomiting                                                               1                339                   Risk Ratio (M‐H, Fixed, 95% CI)       0.77 \[0.53, 1.10\]
  8.4 Itching                                                                1                339                   Risk Ratio (M‐H, Fixed, 95% CI)       1.00 \[0.73, 1.38\]
  8.5 Visual abnormalities                                                   1                339                   Risk Ratio (M‐H, Fixed, 95% CI)       1.00 \[0.72, 1.39\]
  [9 Spontaneous abortion](#CD000169-fig-00109){ref-type="fig"}              10               8643                  Risk Ratio (M‐H, Fixed, 95% CI)       0.77 \[0.56, 1.05\]
  9.1 Para 0‐1                                                               7                2876                  Risk Ratio (M‐H, Fixed, 95% CI)       0.65 \[0.41, 1.02\]
  9.2 All women                                                              3                5767                  Risk Ratio (M‐H, Fixed, 95% CI)       0.89 \[0.58, 1.36\]
  [10 Stillbirth](#CD000169-fig-00110){ref-type="fig"}                       9                9833                  Risk Ratio (M‐H, Fixed, 95% CI)       1.01 \[0.79, 1.28\]
  10.1 Para 0‐1                                                              4                2703                  Risk Ratio (M‐H, Fixed, 95% CI)       0.97 \[0.63, 1.49\]
  10.2 All women                                                             5                7130                  Risk Ratio (M‐H, Fixed, 95% CI)       1.02 \[0.76, 1.36\]
  [11 Perinatal deaths](#CD000169-fig-00111){ref-type="fig"}                 6                6836                  Risk Ratio (M‐H, Fixed, 95% CI)       0.99 \[0.81, 1.22\]
  11.1 Para 0‐1                                                              2                1620                  Risk Ratio (M‐H, Fixed, 95% CI)       0.73 \[0.54, 1.00\]
  11.2 All women                                                             4                5216                  Risk Ratio (M‐H, Fixed, 95% CI)       1.24 \[0.94, 1.63\]
  [12 Neonatal and infant mortality](#CD000169-fig-00112){ref-type="fig"}    9                10486                 Risk Ratio (M‐H, Fixed, 95% CI)       0.93 \[0.76, 1.14\]
  12.1 Para 0‐1 (neonatal death: day 0‐28)                                   3                2156                  Risk Ratio (M‐H, Fixed, 95% CI)       0.62 \[0.37, 1.05\]
  12.2 Para 1+ (deaths up to six weeks)                                      1                2017                  Risk Ratio (M‐H, Fixed, 95% CI)       1.46 \[0.90, 2.38\]
  12.3 All women (neonatal and infant death: day 0‐1 year)                   5                6313                  Risk Ratio (M‐H, Fixed, 95% CI)       0.91 \[0.71, 1.16\]
  [13 Preterm birth](#CD000169-fig-00113){ref-type="fig"}                    5                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  13.1 Para 0‐1                                                              3                1493                  Risk Ratio (M‐H, Fixed, 95% CI)       0.85 \[0.66, 1.10\]
  13.2 All women                                                             2                1174                  Risk Ratio (M‐H, Fixed, 95% CI)       0.95 \[0.65, 1.38\]
  [14 Low birthweight](#CD000169-fig-00114){ref-type="fig"}                  13                                     Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  14.1 Para 0‐1                                                              10               3619                  Risk Ratio (M‐H, Fixed, 95% CI)       0.73 \[0.61, 0.87\]
  14.2 Multigravidae                                                         3                2743                  Risk Ratio (M‐H, Fixed, 95% CI)       0.86 \[0.65, 1.15\]
  14.3 All women                                                             4                3644                  Risk Ratio (M‐H, Fixed, 95% CI)       1.06 \[0.89, 1.27\]
  [15 Mean birthweight (baby)](#CD000169-fig-00115){ref-type="fig"}          15                                     Mean Difference (IV, Fixed, 95% CI)   Subtotals only
  15.1 Para 0‐1                                                              11               3936                  Mean Difference (IV, Fixed, 95% CI)   92.72 \[62.05, 123.39\]
  15.2 All women                                                             5                6007                  Mean Difference (IV, Fixed, 95% CI)   ‐0.54 \[‐24.66, 23.58\]
  [16 Cord blood anaemia](#CD000169-fig-00116){ref-type="fig"}               2                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  16.1 Para 0‐1                                                              1                64                    Risk Ratio (M‐H, Fixed, 95% CI)       2.94 \[0.78, 11.05\]
  16.2 All women                                                             1                870                   Risk Ratio (M‐H, Fixed, 95% CI)       0.49 \[0.30, 0.80\]
  [17 Cord blood haemoglobin](#CD000169-fig-00117){ref-type="fig"}           2                                      Mean Difference (IV, Fixed, 95% CI)   Subtotals only
  17.1 Para 0‐1                                                              1                64                    Mean Difference (IV, Fixed, 95% CI)   ‐1.80 \[‐3.46, ‐0.14\]
  17.2 All women                                                             1                990                   Mean Difference (IV, Fixed, 95% CI)   1.01 \[0.05, 1.97\]
  [18 Placental parasitemia (fetus)](#CD000169-fig-00118){ref-type="fig"}    13                                     Risk Ratio (M‐H, Random, 95% CI)      Subtotals only
  18.1 Para 0‐1                                                              9                2830                  Risk Ratio (M‐H, Random, 95% CI)      0.54 \[0.43, 0.69\]
  18.2 All women                                                             4                3200                  Risk Ratio (M‐H, Random, 95% CI)      0.44 \[0.15, 1.29\]
  [19 Cord blood parasitaemia](#CD000169-fig-00119){ref-type="fig"}          3                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  19.1 Para 0‐1                                                              2                1335                  Risk Ratio (M‐H, Fixed, 95% CI)       0.47 \[0.22, 1.01\]
  19.2 All women                                                             1                2629                  Risk Ratio (M‐H, Fixed, 95% CI)       0.73 \[0.47, 1.14\]
  [20 Adverse effects (baby)](#CD000169-fig-00120){ref-type="fig"}           5                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  20.1 Neonatal icterus                                                      3                2233                  Risk Ratio (M‐H, Fixed, 95% CI)       0.84 \[0.63, 1.13\]
  20.2 Congenital anomalies                                                  2                1328                  Risk Ratio (M‐H, Fixed, 95% CI)       3.53 \[0.58, 21.33\]

![Analysis\
Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 1 Death (mother).](nCD000169-CMP-001-01){#CD000169-fig-00101}

![Analysis\
Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 2 Severe anaemia (mother).](nCD000169-CMP-001-02){#CD000169-fig-00102}
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Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 7 Adverse effects with SP.](nCD000169-CMP-001-07){#CD000169-fig-00107}
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Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 8 Adverse effects with mefloquine.](nCD000169-CMP-001-08){#CD000169-fig-00108}
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Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 9 Spontaneous abortion.](nCD000169-CMP-001-09){#CD000169-fig-00109}
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Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 12 Neonatal and infant mortality.](nCD000169-CMP-001-12){#CD000169-fig-00112}

![Analysis\
Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 13 Preterm birth.](nCD000169-CMP-001-13){#CD000169-fig-00113}

![Analysis\
Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 14 Low birthweight.](nCD000169-CMP-001-14){#CD000169-fig-00114}

![Analysis\
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![Analysis\
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![Analysis\
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Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 20 Adverse effects (baby).](nCD000169-CMP-001-20){#CD000169-fig-00120}

###### IPT with SP versus placebo/no intervention

  Outcome or subgroup title                                                 No. of studies   No. of participants   Statistical method                    Effect size
  ------------------------------------------------------------------------- ---------------- --------------------- ------------------------------------- --------------------------
  [1 Death (mother)](#CD000169-fig-00201){ref-type="fig"}                   3                1926                  Risk Ratio (M‐H, Fixed, 95% CI)       0.99 \[0.30, 3.22\]
  [2 Severe anaemia (mother)](#CD000169-fig-00202){ref-type="fig"}          4                2503                  Risk Ratio (M‐H, Random, 95% CI)      0.60 \[0.47, 0.75\]
  [3 Anaemia (mother)](#CD000169-fig-00203){ref-type="fig"}                 5                3219                  Risk Ratio (M‐H, Random, 95% CI)      0.88 \[0.81, 0.96\]
  [4 Mean haemoglobin (g/dL)](#CD000169-fig-00204){ref-type="fig"}          5                2995                  Mean Difference (IV, Fixed, 95% CI)   0.41 \[0.27, 0.54\]
  [5 Parasitaemia (mother)](#CD000169-fig-00205){ref-type="fig"}            7                3456                  Risk Ratio (M‐H, Random, 95% CI)      0.38 \[0.24, 0.59\]
  [6 Clinical malaria (mother)](#CD000169-fig-00206){ref-type="fig"}        1                174                   Risk Ratio (M‐H, Random, 95% CI)      0.24 \[0.05, 1.12\]
  [7 Spontaneous abortion](#CD000169-fig-00207){ref-type="fig"}             5                2572                  Risk Ratio (M‐H, Fixed, 95% CI)       0.61 \[0.38, 0.99\]
  [8 Stillbirth](#CD000169-fig-00208){ref-type="fig"}                       3                2572                  Risk Ratio (M‐H, Fixed, 95% CI)       0.96 \[0.62, 1.50\]
  [9 Perinatal deaths](#CD000169-fig-00209){ref-type="fig"}                 1                1237                  Risk Ratio (M‐H, Fixed, 95% CI)       0.78 \[0.52, 1.17\]
  [10 Neonatal and infant mortality](#CD000169-fig-00210){ref-type="fig"}   3                2156                  Risk Ratio (M‐H, Fixed, 95% CI)       0.62 \[0.37, 1.05\]
  [11 Preterm birth](#CD000169-fig-00211){ref-type="fig"}                   3                1493                  Risk Ratio (M‐H, Fixed, 95% CI)       0.85 \[0.66, 1.10\]
  [12 Low birthweight](#CD000169-fig-00212){ref-type="fig"}                 7                3043                  Risk Ratio (M‐H, Fixed, 95% CI)       0.81 \[0.67, 0.99\]
  [13 Mean birthweight (baby)](#CD000169-fig-00213){ref-type="fig"}         6                2693                  Mean Difference (IV, Fixed, 95% CI)   105.50 \[68.02, 142.98\]
  [14 Placental parasitemia (fetus)](#CD000169-fig-00214){ref-type="fig"}   6                2257                  Risk Ratio (M‐H, Random, 95% CI)      0.45 \[0.33, 0.61\]
  [15 Cord blood parasitaemia](#CD000169-fig-00215){ref-type="fig"}         2                1335                  Risk Ratio (M‐H, Fixed, 95% CI)       0.47 \[0.22, 1.01\]
  [16 Adverse effects (baby)](#CD000169-fig-00216){ref-type="fig"}          4                3250                  Risk Ratio (M‐H, Fixed, 95% CI)       0.85 \[0.64, 1.15\]
  16.1 Neonatal icterus                                                     3                2233                  Risk Ratio (M‐H, Fixed, 95% CI)       0.84 \[0.63, 1.13\]
  16.2 Congenital anomalies                                                 1                1017                  Risk Ratio (M‐H, Fixed, 95% CI)       2.94 \[0.12, 71.90\]
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Characteristics of included studies \[ordered by study ID\] {#CD000169-sec2-0022}
===========================================================

[Challis 2004 MOZ](#CD000169-bbs2-0001){ref-type="ref-list"}MethodsTrial design: RCT\
Data collected: 2001 to 2002\
Length of follow‐up: from first antenatal visit to first week after delivery\
Frequency of follow‐up: monthlyParticipantsParity: 0‐1\
Number: 600\
Inclusion criteria: nulliparous and primiparous women under 21 years\
Excluded: none statedInterventionsSP (3 tablets): at enrolment and in third trimesterPlacebo\
Other: clinical malaria symptoms treated with CQ, SP or quinine and tetracycline irrespective of allotment\
Administration supervised: yesOutcomesParasitaemia at second visitPlacenta malariaBirthweightNotesLocation: Mozambique\
Urban/rural: both (women from Matola ‐ town and Boane ‐ village)\
Malaria transmission: 20% prevalence\
Drug resistance: chloroquine resistance present\
HIV prevalence: 10%\
Funding: Department of Research Co‐operation with Developing countries (SAREC) at the Swedish International Development Authority (Sida) and from Mid Sweden Research and Development Centre (FoU)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"The data were analysed on an ITT basis. ITT includes a random allocation procedure producing comparable groups and an analysis of the data according to the way we intended to treat the subjects\".\
Women were \"randomly assigned\" to receive SP or placebo. No sufficient information provided how the allocation sequence was generated.Allocation concealment (selection bias)Unclear riskPackages of SP or placebo tablets.Blinding (performance bias and detection bias)   All outcomesLow risk\"Three tablets (SP or placebo) were given in a double‐blind manner: either SP/SP -- an initial treatment dose of SP at enrolment with a second dose at the beginning of the third trimester; or placebo/placebo...The placebo dose was three similar tablets in shape and colour as SP tablets.\"Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNo details provided, except that all slides were analysed and double checked at the malaria laboratory at the Ministry of Health.Incomplete outcome data (attrition bias)   All outcomesHigh riskAt second dose: 189/600 = 31.5% lost to follow‐up.\
At delivery: 309/600 women = 51.5% lost to the follow‐up peripheral blood analyses (153/300 = 51% from the placebo group and 156/300 = 52% from the SP group).Selective reporting (reporting bias)Low riskNo selective reporting observed.Other biasLow riskNone identified.[Cot 1992 BFA](#CD000169-bbs2-0002){ref-type="ref-list"}MethodsTrial design: Quasi‐RCT\
Data collected: 1987 to 1988\
Length of follow‐up: approximately five months (from the first visit to the clinic which was for most women before the 5th month of pregnancy, until delivery)\
Frequency of follow‐up: twice a weekParticipantsParity: all women\
Number: 1464\
Inclusion criteria: every pregnant woman attending urban maternal and child health centre\
Excluded: none statedInterventionsChloroquine: weeklyNothing\
Other: no information\
Administration supervised: yesOutcomesPlacental parasitaemiaMean birthweight and low birthweightNotesLocation: Burkina Faso\
Urban/rural: urban (the city of Banfora)\
Malaria transmission: hyperendemic, with seasonal transmission\
Drug resistance: chloroquine resistance may be present\
19% parasitaemia in trial population\
Funding: INSERM (Institut National de Ia Santé et de Ia Recherche Médicale): Reseau Nord‐Sud no. 486 NS2.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High risk\"For the sake of simplicity, an alternate allocation of treatment was performed, in which the women were divided into two groups (treated and control).\"\
No specific procedure used to generate allocation sequence.Allocation concealment (selection bias)High riskAllocation not concealed.Blinding (performance bias and detection bias)   All outcomesHigh risk\"For technical reasons, it was not possible to give a placebo to women in the control group.\"\
Participants and personnel were not blinded.Blinding of outcome assessment (detection bias)   All outcomesLow risk\"Laboratory technicians had no information on the status of the individuals from whom the samples had been taken, as did the midwives who weighed the newborn babies\"\
Outcome assessors were blinded.Incomplete outcome data (attrition bias)   All outcomesHigh riskHigh attrition rate: 263/1464 (17.96%). There were 20.3 % (151/745 women) with no outcome in the experimental arm (chloroquine): 29 excluded after randomization (stillbirths, abortions, multiple pregnancies). The other 122/745 women (16.4%) delivered outside of the hospital. There were 22.9% (165/719 women) with no outcome in the control arm: 24 excluded, 141/719 (19.6%) delivered outside of the hospital.Selective reporting (reporting bias)Low riskNo selective reporting observed.Other biasUnclear riskApproximately 20 women were allocated to the control group at the beginning of the trial and reclassified in the treated group a few days later. \"These subjects were not clearly identified, and it was impossible to exclude them afterwards.\"[Cot 1995 CMR](#CD000169-bbs2-0003){ref-type="ref-list"}MethodsTrial design: Quasi‐RCT\
Data collected: 1991 to 1993\
Length of follow‐up: from first prenatal visit until delivery (two to five months)\
Frequency of follow‐up: weeklyParticipantsParity: para 0\
Number: 266\
Inclusion criteria: primigravidae antenatal clinic attendees\
Excluded: none statedInterventionsChloroquine: 300 mg per week until deliveryNothing\
Other: no information\
Administration supervised: yesOutcomesAntenatal parasitaemiaPlacental malariaBirthweightNotesLocation: Cameroon\
Urban/rural: urban (town of Ebolowa)\
Malaria transmission: hyperendemic area with high transmission all year round\
Drug resistance: moderate chloroquine resistance\
Funding: Ministère Français de la Coopération (FAC paludisme)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High risk\"After being examined by the hospital physician, any primigravida living in the study area and attending the clinic for a first prenatal visit... was introduced to an investigator who obtained their informed consent and allocated them alternately to a chloroquine treatment (CQ) group or a control (CT) group.\"\
Trial described as \"randomized, double‐blind\", but participants were \"alternately allocated\".Allocation concealment (selection bias)High riskAllocation not concealed.Blinding (performance bias and detection bias)   All outcomesHigh risk\"Women in the control group followed the usual hospital procedures; placebos were not used\".\
Not blinded.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskUnclear whether outcome assessors were blinded. No information provided.Incomplete outcome data (attrition bias)   All outcomesHigh riskAttrition rate was 21.4% (28/131) in the experimental arm (chloroquine) and 21.5% (29/135) in the control arm for the duration of the pregnancy.Selective reporting (reporting bias)Low riskNo selective reporting observed. Antenatal parasitaemia not clearly reported.Other biasHigh risk\"Of the CT group women, 39 (56%) declared that on their own initiative, they had taken one or more short treatments of either chloroquine or amodiaquine during the course of their pregnancy because they thought they had contracted malaria.\" Possible protocol violation.[Fleming 1986 NGA](#CD000169-bbs2-0004){ref-type="ref-list"}MethodsTrial design: RCT\
Data collected: unclear (before 1985). First attendance to the clinic: 1977 to 1978\
Length of follow‐up: from first prenatal visit until 6 weeks after delivery\
Frequency of follow‐up: at least once every two weeks up to the 36th week of gestation and subsequently, weekly until delivery\
Haematological observations were performed at first attendance, 28 weeks and 36 weeks of gestation, at delivery and 6 weeks postpartumParticipantsParity: para 0\
Number: 200\
Inclusion criteria: primigravidae under 16 years attending antenatal clinic; Hausa tribe\
Excluded: severe anaemiaInterventionsProguanil dailyPlacebo\
Other: all received single dose chloroquine on entry; folic acid and iron supplements included in randomized design\
Administration supervised: noOutcomesAntenatal parasitaemia and haemoglobinBirthweightNotesLocation: Nigeria\
Urban/rural: urban (Zaria)\
Malaria transmission: unstable area with seasonal transmission\
Drug resistance: none\
Funding: WHO, Ahmadu Bello University, Smith Kline and French Laboratories Ltd (UK) and Imperial Chemical Industries***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskParticipants \"randomly allocated\" to one of five treatment groups, using random numbers table.Allocation concealment (selection bias)Low risk\"Neither the researchers nor the patients were aware of the treatment allocated until after the completion of the study.\"\
Treatment allocation code was used.Blinding (performance bias and detection bias)   All outcomesLow risk\"The manufacturers supplied active tablets or spansules and the placebos, which could not be distinguished by sight.\"Blinding of outcome assessment (detection bias)   All outcomesUnclear riskUnclear whether outcome assessors were blinded. No information provided.Incomplete outcome data (attrition bias)   All outcomesHigh risk\"Only 89 women out of 200 delivered in the hospital\... 12/200 (6%) did not attend again (the clinic) after the first or second visits; a further 72/200 (36%) did not continue until the postnatal visit.\"\
Inadequate details but there is evidence to suggest that the attrition rate was quite high.Selective reporting (reporting bias)Low riskNo selective reporting observed.Other biasUnclear risk\"18 patients were replaced in the trial by others; this was arranged by a moderator (Dr. B. M. Greenwood), who was not otherwise involved in the research, but had access to the treatment allocation code for this purpose...Eighteen patients were replaced in the trial by others.\"[Greenwood 1989 GMB](#CD000169-bbs2-0005){ref-type="ref-list"}MethodsTrial design: Trial randomized by compound\
Data collected: 1984 to 1987\
Length of follow‐up: from first prenatal visit until one week after delivery\
Frequency of follow‐up: unclear but administration was on weekly basisParticipantsParity: all women\
Number: 1049\
Inclusion criteria: all women in trial villages who became pregnant; some sub‐studies only followed up primigravidae\
Excluded: none statedInterventionsPyrimethamine 25 mg and dapsone 100 mg: fortnightlyPlacebo\
Given by village people employed by the project\
Other: no information\
Administration supervised: yesOutcomesAntenatal parasitaemiaBirthweightPacked cell volumeMaternal deathPerinatal deathInfant deathNotesLocation: The Gambia\
Urban/rural: urban\
Malaria transmission: seasonal\
Drug resistance: none reported\
Funding: Unclear\
For the analysis we assumed that it is individually RCT***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Once a woman had reported to a traditional birth attendant that she was pregnant, she was allocated to receive one tablet of Maloprim fortnightly or placebo and issued with a record card by an MRC field worker. Randomization was by compound.\"\
No details provided of a specific procedure used to generate allocation sequence.Allocation concealment (selection bias)Unclear risk\"Treatment was indicated on the record card by a pictorial representation of a coloured tablet (white for Maloprim,  pink for placebo)\".\
Insufficient details provided.Blinding (performance bias and detection bias)   All outcomesLow riskPlacebo tablets used.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNo details provided.Incomplete outcome data (attrition bias)   All outcomesUnclear risk\"1208 pregnancies which progressed beyond the 28th week were recorded during the 3 years of the survey. During 1049 (87%) of these pregnancies women reported to the TBA resident and received one or more doses of Maloprim or placebo.\"\
Unclear risk. Assumption is that attrition rate was 13.2% (159/1208, where 159 = 1208‐1049).Selective reporting (reporting bias)Low riskNo apparent risk.Other biasLow riskNone identified.[Mbaye 2006 GMB](#CD000169-bbs2-0006){ref-type="ref-list"}MethodsTrial design: RCT\
Data collected: 2002 to 2004\
Length of follow‐up: From the 1st antenatal visit to 1 year after delivery\
Frequency of follow‐up: twice per week before delivery; 6 weeks and 1 year after deliveryParticipantsParity: multigravidae only\
Number: 2688\
Inclusion criteria: pregnancy of more than 15 weeks duration\
Excluded: Hb concentration of \< 7 g/dL; allergy to sulphonamides; severe or chronic diseaseInterventions3 tablets of SP (up to 4 drug administrations; mean gap 29 days)3 tablets of placebo (up to 4 administrations; mean gap 28 days)\
Other: iron and folic acid for all\
Administration supervised: yesOutcomesMaternal mortalityPrevalence of peripheral parasitaemia after deliveryAnaemia/HbBirth outcomesInfant death (death by 6 weeks)NotesLocation: The Gambia\
Urban/rural: urban (around the town Farafenni)\
Malaria transmission: seasonal\
Drug resistance: unknown\
HIV: HIV negative women; prevalence of HIV infection among antenatal clinic attenders \< 1%\
Funding: The Medical Research Council and the Gates Malaria Partnership, funded by the Bill and Melinda Gates foundation***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"Women were individually randomized in blocks of 12\".Allocation concealment (selection bias)Low risk\"Tablets were pre‐packed in envelopes...pre‐labelled with the same packet number and placed in a wallet bearing the subject's number and packet number.\"Blinding (performance bias and detection bias)   All outcomesLow riskIdentical SP and placebo tablets used.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNo information provided.Incomplete outcome data (attrition bias)   All outcomesHigh riskAttrition rate quite high: 459/2688 (17.1 %): Loss to follow‐up in SP group 223/1346 (16.6%) and in the placebo group 236/1342 (17.6%).Selective reporting (reporting bias)Low riskNo apparent risk.Other biasUnclear riskLimited information obtained on bednet use (an important variable in determining the efficacy of IPT). Actual birthweights obtained from only 5% of women (87% of the newborn babies were weighed between 3 and 5 days after birth).[Menendez 1994 GMB](#CD000169-bbs2-0007){ref-type="ref-list"}MethodsTrial design: Cluster‐RCT\
Data collected: 1987 to 1990\
Length of follow‐up: from first antenatal visit to third day after delivery\
Frequency of follow‐up: unclear but administration by traditional birth attendants was on weekly basisParticipantsParity: 0\
Number: 230\
Inclusion criteria: primigravidae resident in trial area\
Excluded: none statedInterventionsPyrimethamine and dapsone: weekly (one tablet of Maloprim weekly: pyrimethamine 12.5 mg and dapsone 100 mg)Placebo\
Given by village people employed by the project\
Other: no information\
Administration supervised: yesOutcomesPlacental malariaPregnancy outcomesBirthweightNeonatal mortalityNotesLocation: The Gambia\
Urban/rural: rural (trial area: 15 villages and 3 hamlets, 12 to 35 km from the town of Farafenni)\
Malaria transmission: seasonal\
HIV: no information provided\
Drug resistance: none reported\
Funding: no information***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskDescribed as \"a randomized, double‐blind, placebo‐controlled community based trial\" but no details of the way allocation sequence was generated are provided.Allocation concealment (selection bias)Unclear risk\"After consent had been obtained, women were randomized by compound of residence to receive weekly either one tablet of Maloprim or placebo.\"\
Comment: insufficient detail.Blinding (performance bias and detection bias)   All outcomesHigh riskNot blinded.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNo information provided.Incomplete outcome data (attrition bias)   All outcomesUnclear riskUnclear.\
\"Two hundred and thirty women were recruited into the study over a 3‐year period...\"\
Afterwards, only 82 women are mentioned as participants in the maloprim group and 89 women in the placebo group. Overall attrition rate 59/230 (25.7%)\
The total number of women with incomplete outcome data 28/230 (12.2%). Four women had an abortion, 17 had stillbirths, five women died, and 2 other women (0.9%) were lost to follow‐up.Selective reporting (reporting bias)Low riskNo selective reporting observed.Other biasLow riskNo other source of bias identified.[Menendez 2008 MOZ](#CD000169-bbs2-0008){ref-type="ref-list"}MethodsTrial design: RCT\
Data collected: August 2003 to April 2005\
Length of follow‐up: from recruitment until 8 weeks postpartum\
Frequency of follow‐up: unclear. Mean number of outpatient visits during pregnancy 1.64 in the SP and 1.83 in the placebo group. Mean number of visits post‐partum 0.69 in the SP group and 0.68 in the placebo groupParticipantsParity: all\
Number: 1030\
Inclusion criteria: permanent residents of the CISM trial area with gestational age ≤ 28 weeks\
Excluded: allergic to sulpha drugsInterventionsTwo doses of SP given at least one month apartPlacebo ‐ same\
Other: ITNs\
Administration supervised: yesOutcomesMaternal mortalityPeripheral parasitaemiaAny placental malaria infection (fever episode)Severe anaemia (PCV \< 21%)Pregnancy outcomesPerinatal mortalityNeonatal mortalityBirthweightPre‐term birthCord blood parasitaemiaCord blood anaemia (PCV \< 37%)Newborn gestational ageNotesLocation: Mozambique\
Urban/rural: urban\
Malaria transmission: perennial malaria transmission with some seasonality\
Drug resistance: evidence suggests that SP was highly effective in the area during the trial\
HIV: In the SP group, 26.5% (117/441 women), and in the placebo group, 21.2% (91/429 women). Overall: 23.9%\
Funding: Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III (grant number CM03/00125); Banco de Bilbao, Vizcaya, Argentaria Foundation (grant number BBVA 02‐0); Spanish Agency for International Cooperation (AECI)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"A computer‐generated sequential list contained the study numbers linked to treatment identification letters, randomly ordered in blocks of 10\".Allocation concealment (selection bias)Low risk\"Tablets of SP or placebo\... were stored in 10 bottles labelled only with a single treatment identification letter.\"Blinding (performance bias and detection bias)   All outcomesLow riskSP and placebo tablets \"identical in shape and colour\".Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNo details provided.Incomplete outcome data (attrition bias)   All outcomesLow riskIn the SP group 35/515 (6.8%) did not receive 2 doses and birthweight was not measured for 7/501 (1.4%) live births. In the placebo group 29/515 (5.6%) did not receive 2 doses and birthweight was not measured for 7/503 (1.4%) live births.Selective reporting (reporting bias)Low riskNone identified (trial protocol available).Other biasUnclear riskData were analysed by ITT analysis whereby all randomized women were included regardless of whether or not they had received the intervention and the number of doses. Women with a multiple delivery (twins or triplets) as well as those who did not receive all three doses were also included in the analysis.[Morley 1964 NGA](#CD000169-bbs2-0009){ref-type="ref-list"}MethodsTrial design: Quasi‐RCT\
Data collected: 1957\
Length of follow‐up: from first antenatal visit to delivery\
Frequency of follow‐up: insufficient detail (drugs given monthly)ParticipantsAll women\
Number: 429\
Inclusion criteria: all pregnant women registered at dispensary\
Excluded: none statedInterventionsPyrimethamine: monthlyPlacebo\
Other: fever treated with chloroquine sulphate in both groups\
Administration supervised: women were given drugs during antenatal visitsOutcomesAntenatal weight gainFever episodesParasitaemiaPlacental infectionBirthweightPerinatal mortalityNotesLocation: Nigeria\
Urban/rural: rural (the village of Imesi)\
Malaria transmission: holoendemic area\
Drug resistance: none\
Funding: no information***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High risk\"As the pregnant women were registered at the dispensary, they were given consecutive numbers and allotted to one or other of two groups. All women with even numbers were given 2 tablets (50 mg) of pyrimethamine once a month... The control group (the odd numbers) were given two tablets of placebo\".\
Comment: not randomized.Allocation concealment (selection bias)Unclear riskInsufficient detail provided.Blinding (performance bias and detection bias)   All outcomesLow riskPyrimethamine and \"similar tablets\" placebo were usedBlinding of outcome assessment (detection bias)   All outcomesLow risk\"Blood films were examined in the hospital laboratory... The technicians did not know to which group a mother belonged.\"\
Assessors blinded.Incomplete outcome data (attrition bias)   All outcomesLow riskBirthweight: data available for 93.7% (402/429 women). Incomplete data outcome for 6.3% (27/429) women: 17 stillbirths and 10 twin deliveries were excluded.Selective reporting (reporting bias)Low riskNo selective reporting observed.Other biasLow riskNone identified.[Nahlen 1989 NGA](#CD000169-bbs2-0010){ref-type="ref-list"}MethodsTrial design: RCT\
Data collected: from January to June 1988\
Length of follow‐up: 77 days (mean interval from day 7 post‐chloroquine treatment to documentation of parasitaemia was 74 days for pyrimethamine group)\
Frequency of follow‐up: weekly. Follow‐up examinations and blood smears were obtained on days 2, 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, and 77ParticipantsParity: all\
Number: 71\
Inclusion criteria: antenatal and attending hospital and health centre; \< 34 weeks gestation; no recent chloroquine taken; parasitaemic \> 500 parasites/µL blood\
Excluded: history of antimalarial drug ingestion during the previous weekInterventionsPyrimethamine (25 mg): weeklyNothing\
Other: treated with two doses of chloroquine at recruitment; folic acid and iron given to all women\
Administration supervised: yesOutcomesAntenatal parasitaemiaNotesLocation: Nigeria\
Urban/rural: urban (Ilorin, the capital of Kwara State)\
Malaria transmission: endemic area\
Drug resistance: possible pyrimethamine resistance present\
Funding: US Agency for International Development, Africa Child Survival‐Initiative‐Combatting Childhood Communicable Diseases Project, 698‐0421***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Women in group 2 were assigned randomly to a pyrimethamine treatment or a control group.\"\
The statement that women were randomly assigned is insufficient to be confident that the allocation sequence was genuinely randomized.Allocation concealment (selection bias)High risk\"The treated group was observed to take 25 mg of pyrimethamine weekly and was instructed to take folic acid and iron supplements daily, while the control group took only folic acid and iron daily.\"\
Allocation not concealed.Blinding (performance bias and detection bias)   All outcomesHigh riskNot blinded.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNo details provided.Incomplete outcome data (attrition bias)   All outcomesLow risk\"In vivo tests were completed successfully in all 71 women enrolled.\"\
Comment: There were no missing outcome data.Selective reporting (reporting bias)Low riskNo apparent risk.Other biasLow riskNone identified.[Ndyomugyenyi 2000 UGA](#CD000169-bbs2-0011){ref-type="ref-list"}MethodsTrial design: RCT\
Data collected: 1996 to 1998\
Length of follow‐up: from first antenatal visit to first week postpartum\
Frequency of follow‐up: monthlyParticipantsParity: 0\
Number: 860\
Inclusion criteria: primigravidae\
Excluded: severe anaemia (\< 8 g)Interventions1. Chloroquine  2. Placebo  3. Iron + folate (not included in the analysis)\
Other: clinical malaria symptoms treated with 25 mg/kg of chloroquine for three days, ITNs\
Administration supervised: noOutcomes1. Haemoglobin  2. BirthweightNotesLocation: Uganda\
Urban/rural: rural (Hoima District)\
Malaria transmission: hyperendemic area\
Drug resistance: unknown\
Funding: The Danish Bilharziasis Laboratory, Denmark***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"After clinical and laboratory examination, women were randomly assigned to 1 of the 3 intervention group\".\
Insufficient details.Allocation concealment (selection bias)Unclear riskNo information provided.Blinding (performance bias and detection bias)   All outcomesLow riskPlacebo and active tablets of the same colour and shape.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNo information provided to make a judgement whether or not the outcome assessors were blinded.Incomplete outcome data (attrition bias)   All outcomesHigh riskA high attrition rate of 32.6% (268 out of 823 women were lost to follow‐up).Selective reporting (reporting bias)Low riskNo apparent risk.Other biasLow riskNone identified.[Ndyomugyenyi 2011 UGA](#CD000169-bbs2-0012){ref-type="ref-list"}MethodsTrial design: individually RCT\
Data collected: 2004 to 2008\
Length of follow‐up: from first antenatal visit to 28 days after delivery\
Frequency of follow‐up: regularly through ANC clinics, and every seven days postnatallyParticipantsParity: all parities\
Number: 5775 randomized; 4715 singleton births followed up\
Inclusion criteria: pregnant women \< 27 weeks at first clinic visit\
Excluded: \> 26 weeks pregnant, non‐residents and temporary residentsInterventionsITNs + placeboITNS + IPTIPT\
Drugs given under direct observation. Two doses of SP.OutcomesPrevalence of maternal anaemia (Hb \< 11.0 g/L)\
mean Hb at 36 to 40 weeks\
Clinical malaria\
Peripheral and placental parasitaemia\
Abortions, preterm births, stillbirths, perinatal deaths, neonatal deaths\
Low birthweight\
Mean birthweightNotesLocation: Kabale Highlands, Uganda\
Urban/rural: rural\
Malaria transmission: low/unstable area\
Drug resistance: SP thought to be effective\
HIV: low\
Funding: Gates Partnership***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"computer‐generated random number list\".Allocation concealment (selection bias)Low risk\"individual sealed envelopes\".Blinding (performance bias and detection bias)   All outcomesLow risk\"Tablets of SP or placebo, identical in shape and colour\".Blinding of outcome assessment (detection bias)   All outcomesLow risk\"All study participants, health staff and researchers were blind to drug assignment (SP or placebo)\".Incomplete outcome data (attrition bias)   All outcomesLow riskDelivery follow‐up: 92%, 92%, and 93% to one month.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNone identified.[Njagi 2003i KEN](#CD000169-bbs2-0014){ref-type="ref-list"}MethodsRCTParticipantsLow parity (0‐1)\
Number: 963\
Inclusion criteria: gestational age of between 12 and 24 weeks\
Exclusion criteria: HIV/AIDS, severe systemic diseasesInterventionsITN + IPT‐SP (2 doses)ITN + placebo (2 doses)\
Other: Folic acid and iron given to all women\
Administration supervised: yesOutcomesMaternal anaemiaMaternal mortalityBirth outcomes: abortions\
Length of follow‐up: From 1st antenatal visit to 1 week after delivery\
Frequency of follow‐up: monthly antenatal clinic visitsNotesLocation: Western Kenya\
Malaria transmission: intense\
Drug resistance: unknown***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated random number sequences in blocks of 12.Allocation concealment (selection bias)Unclear riskNo details provided.Blinding (performance bias and detection bias)   All outcomesLow risk\"Placebo and active drug tablets were of equal size, colour and shape. The investigators had no knowledge of the assigned groups until after data collection, editing and data analysis were completed.\"Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNo details.Incomplete outcome data (attrition bias)   All outcomesHigh riskAttrition rate 17.4% (168/963): 114 lost due to migration, 35 -- home delivery, 19 -- refused to continue. Attrition rate in ITN and SP group 35/242 (14.5%), in ITN and placebo group 32/238 (13.4%), in SP group 52/245 (21.2%), in placebo group 49/238 (20.6%). Together with the exclusions, 211/963 (21.9%) women with no treatment outcome.Selective reporting (reporting bias)Unclear riskMentioned that mode of delivery, birthweight and baby's Hb were recorded but they were never reported. The trial report fails to include results for a key outcome that would be expected to have been reported for such a trial.Other biasLow riskNone identified.[Njagi 2003ii KEN](#CD000169-bbs2-0013){ref-type="ref-list"}MethodsAs for [Njagi 2003i KEN](#CD000169-bbs2-0014){ref-type="ref-list"}ParticipantsAs for [Njagi 2003i KEN](#CD000169-bbs2-0014){ref-type="ref-list"}InterventionsIPT‐SP (2 doses)Placebo (2 doses)\
Other: Folic acid and iron given to all womenOutcomesAs for [Njagi 2003i KEN](#CD000169-bbs2-0014){ref-type="ref-list"}NotesAs for [Njagi 2003i KEN](#CD000169-bbs2-0014){ref-type="ref-list"}***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated random number sequences in blocks of 12.Allocation concealment (selection bias)Unclear riskNo details provided.Blinding (performance bias and detection bias)   All outcomesLow risk\"Placebo and active drug tablets were of equal size, colour and shape. The investigators had no knowledge of the assigned groups until after data collection, editing and data analysis were completed.\"Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNo details.Incomplete outcome data (attrition bias)   All outcomesHigh riskAttrition rate 17.4% (168/963): 114 lost due to migration, 35 -- home delivery, 19 -- refused to continue. Attrition rate in ITN and SP group 35/242 (14.5%), in ITN and placebo group 32/238 (13.4%), in SP group 52/245 (21.2%), in placebo group 49/238 (20.6%). Together with the exclusions, 211/963 (21.9%) women with no treatment outcome.Selective reporting (reporting bias)Unclear riskMentioned that mode of delivery, birthweight and baby\'s Hb were recorded but they were never reported. The trial report fails to include results for a key outcome that would be expected to have been reported for such a trial.Other biasLow riskNone identified.[Nosten 1994 THA](#CD000169-bbs2-0015){ref-type="ref-list"}MethodsTrial design: RCT\
Data collected: 1987 to 1990\
Length of follow‐up: from first antenatal visit at \> 20 weeks of estimated gestation to 2 years after delivery\
Frequency of follow‐up: weeklyParticipantsParity: all\
Number: 339\
Inclusion criteria: antenatal attendees \> 20 weeks of gestation\
Excluded: none statedInterventionsMefloquine: weeklyNothing\
Other: treated antenatally if parasitaemic; given folic acid and iron if anaemic\
Administration supervised: yesOutcomesAntenatal episodes of parasitaemiaAnaemiaPreterm birthBirthweightPerinatal deathNotesLocation: Thailand\
Urban/rural: rural (camps Wangka, Shoklo, Bonoko)\
Malaria transmission: unstable malarious area (mesoendemic)\
Drug resistance: multiple drug resistance present\
Funding: United Nations Development Programme/World Bank/WHO Special Programme for Research and Training in Tropical Diseases; Wellcome Trust of Great Britain; Prevention Foundation, The Hague***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskTrial described as \"a double‐blind, placebo‐controlled trial\". No details provided of the sequence generation method used.Allocation concealment (selection bias)Unclear riskNo details provided.Blinding (performance bias and detection bias)   All outcomesLow riskPlacebo tablets identical with treatments were used.\
\"The investigators were unaware of the randomization\".Blinding of outcome assessment (detection bias)   All outcomesUnclear riskBlinding of outcome assessors not mentioned.Incomplete outcome data (attrition bias)   All outcomesLow riskAttrition rate 8% (10/119) in Phase 1 and 8% (18/220) in Phase 2. Across groups: 7.1% (12/170) were excluded from the mefloquine group and 9.5% (16/169) were excluded from the placebo group. Explanation provided.Selective reporting (reporting bias)Low riskNo apparent risk.Other biasLow riskNone identified.[Parise 1998i KEN](#CD000169-bbs2-0017){ref-type="ref-list"}MethodsTrial design: Quasi‐RCT\
Data collected:1994 to 1996\
Length of follow‐up: from first antenatal visit to delivery; for infants: follow‐up at 3‐7 days of life and at 6 weeks of age\
Frequency of follow‐up: at two and four weeks after enrolment and then monthly until deliveryParticipantsParity: para 0‐1\
Number: 2077\
Inclusion criteria: antenatal clinic attendees; first or second pregnancy\
Excluded: prior ADRs to sulfa‐containing or other antimalarial medicationsInterventionsSP: treatment dose, repeated in late pregnancy (2 doses); not administered at intervals of less than 1 monthNo intermittent preventive treatment, SP given with recent history of fever or parasitaemia\
Other: 200 mg ferrous sulphate and 5 mg folic acid daily\
Administration supervised: YesOutcomesMaternal anaemiaMean haemoglobinPlacental infectionBirthweightPreterm birthStillbirthNeonatal deathNotesLocation: Kenya\
Urban/rural: urban\
Malaria transmission: hyperendemic area\
Drug resistance: chloroquine\
HIV seroprevalence : 2SP ‐ 26.9% (53/196); Case management ‐ 26.9% (57/212)\
Funding: UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (ID No. 940060); the US Agency for International Development through the Health and Human Resources Analysis for Africa (HHRAA) Project through a Participating Agency Service Agreement (PASA number AOT‐0483‐P‐HI‐2171)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High risk\"Women were systematically assigned to receive one of three regimens using a rotating assignment based on day of clinic visit.\"\
Comment: allocation was not random.Allocation concealment (selection bias)High riskAllocation schedule not concealed.Blinding (performance bias and detection bias)   All outcomesHigh riskNo blinding. Women were systematically assigned to receive either two‐dose SP with treatment doses at enrolment\
and again early in the third trimester, or case management (CM).Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNo details provided.Incomplete outcome data (attrition bias)   All outcomesHigh risk\"Six hundred ninety‐nine women (34%) were lost to follow‐up during pregnancy because they moved out of the study area or failed to return for follow‐up and the study team was unable to locate their houses.\"\
Data was not available for 36.5% (248/680) women in the 2 SP and 35.9% (264/736) women in the case management group.Selective reporting (reporting bias)Low riskThe trial protocol was available. No selective reporting observed.Other biasLow riskNo apparent risk.[Parise 1998ii KEN](#CD000169-bbs2-0016){ref-type="ref-list"}MethodsAs for [Parise 1998i KEN](#CD000169-bbs2-0017){ref-type="ref-list"}ParticipantsAs for [Parise 1998i KEN](#CD000169-bbs2-0017){ref-type="ref-list"}InterventionsSP: monthly with treatment doses at enrolment and then monthly through 34 weeks of gestationNo intermittent preventive treatment, SP given with recent history of fever or parasitaemiaOutcomesAs for [Parise 1998i KEN](#CD000169-bbs2-0017){ref-type="ref-list"}NotesAs for [Parise 1998i KEN](#CD000169-bbs2-0017){ref-type="ref-list"}\
HIV seroprevalence: Monthly SP ‐ 23.7% (40/169); Case management ‐ 26.9% (57/212)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High risk\"Women were systematically assigned to receive one of three regimens using a rotating assignment based on day of clinic visit.\"\
Comment: allocation was not random.Allocation concealment (selection bias)High riskAllocation schedule not concealed.Blinding (performance bias and detection bias)   All outcomesHigh riskNo blinding.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNo details provided as to whether the outcome assessors were blinded.Incomplete outcome data (attrition bias)   All outcomesHigh riskSix hundred ninety‐nine women (34%) were lost to follow‐up. Data was not available for 34.8% (230/661) in the monthly SP and 35.9% (264/736) in the case management group.Selective reporting (reporting bias)Low riskNo selective reporting observed.Other biasLow riskNone identified.[Shulman 1999 KEN](#CD000169-bbs2-0018){ref-type="ref-list"}MethodsTrial design: RCT\
Data collected: 1996 to 1997\
Length of follow‐up: from first antenatal visit to one month post delivery (neonatal period)\
Frequency of follow‐up: unclear (drug administered as follows: three doses for women recruited at 16 to 19 weeks of gestation; two for those recruited at 20 to 26 weeks; and one for those recruited at 27 to 30 weeks, followed by a visit at 34 weeks and a visit 4 weeks after delivery).ParticipantsParity: 0\
Number: 1264\
Inclusion criteria: primigravidae attending antenatal clinics at a health centre (1) or hospital (1); singleton pregnancy; 16 to 30 weeks gestation\
Excluded: severely anaemic and sick patients excludedInterventionsSP: recruited at 16 to 19 weeks (2 doses); 20 to 26 weeks (2 doses); 27 to 30 weeks (1 dose)Placebo\
Other: ferrous sulphate; impregnated bed nets in use in the area\
Administration supervised: yesOutcomesAntenatal: parasitaemia and haemoglobin at 34 weeksStillbirthNeonatal deathMaternal deathMorbidityNotesLocation: Kenya\
Urban/rural: rural (Kilifi)\
Malaria transmission: hyperendemic and mesoendemic areas\
Drug resistance: present\
Funding: UK Department for International Development and KEMRI***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"Participants were assigned unique identification numbers sequentially... identification numbers had been randomly allocated to a number between zero and nine, in blocks of ten.\"\
Comment: randomization method, using permuted blocksAllocation concealment (selection bias)Low riskDrugs supplied in bottles.\
\"Questionnaires were premarked with this unique identification number and the bottle number. The code relating bottle numbers to their contents was retained by a statistician and clinician, not involved in the study.\"\
Comment: allocation concealed.Blinding (performance bias and detection bias)   All outcomesLow riskSP and placebo tablets, \"identical in appearance and taste\".Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot clear whether outcome assessors were blinded.Incomplete outcome data (attrition bias)   All outcomesUnclear riskAttrition rate 11.41% (73/640) in the SP group and 9.5 % (59/624) in the placebo group, signifying the number of women with no blood test during third trimester.Selective reporting (reporting bias)Low riskTrial protocol available; no apparent risk of selective reporting identified.Other biasUnclear riskProtocol violation: 6 women from SP group and 8 from placebo group reported taking extra doses of SP (unclear whether women from the placebo group took placebo tablets, or real SP).\
69 women from SP group reported taking chloroquine.\
61 women from placebo group reported taking chloroquine.[Villegas 2007 THA](#CD000169-bbs2-0019){ref-type="ref-list"}MethodsTrial design: RCT\
Data collected: November 1998 to January 2000 (infant follow‐up completed in December 2001)\
Length of follow‐up: Mother: from the first antenatal visit to delivery; infant follow‐up completed 1 year after delivery\
Frequency of follow‐up: weeklyParticipantsParity: all\
Number: 951\
Inclusion criteria: pregnant women of all parities, of any gestational age, with a negative malaria smear and able to comply with the trial protocol\
Excluded: allergy to chloroquine, inability to tolerate oral drugs, severe renal or hepatic impairment, tuberculosis treatment, a history of epilepsy or diabetes mellitus or both, or signs of labour InterventionsChloroquine: 4 tablets (250 mg chloroquine phosphate, 153 mg base) given on enrolment. Two tablets of the same type given on a weekly basis afterwards, until delivery.Placebo\
Other: ferrous sulphate + folic acid\
Administration supervised: yesOutcomesMaternal mortality*P. vivax* and *P. falciparum* parasitaemiaAnaemiaBirth outcomes (miscarriage, stillbirth)Birthweight (mean and low birthweight)PrematurityNotesLocation: Thailand\
Urban/rural: rural (Maela Refugee Camp and the vicinity of Maw Ker Tai village)\
Malaria transmission: low, seasonal transmission\
Drug resistance: possible chloroquine resistance\
HIV prevalence: no information\
Funding: Wellcome Trust of Great Britain, Ministerio de Salud de Venezuela (Proyecto Control de Enfermedades), the UNDP/World Bank/WHO Special Programme for Research training in Tropical Diseases (Research Training Grant)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"Participants were assigned unique identification numbers sequentially. All identification numbers were allocated randomly by computer to a number between one and ten, in blocks of ten (five randomly allocated to CQ and five to placebo in each block)\".\
Randomization method, using permuted blocks.Allocation concealment (selection bias)Low risk\"Each unique identification number was linked to a brown paper envelope which contained the study drugs in weekly allotments, sealed into zippered plastic bags... labelled with week number of the study. The preparation of the study drugs was done in Mae Sot by the SMRU pharmacist who was not involved with any other aspect of the study. The study codes and randomization list was retained by a clinician at SMRU\...\"\
Allocation was concealed.Blinding (performance bias and detection bias)   All outcomesLow riskPlacebo and active tablets, \"identical in appearance and taste\".Blinding of outcome assessment (detection bias)   All outcomesLow risk\"The investigators and staff participating in the trial were unaware of the study codes until data collection was completed.\"\
Outcome assessors were probably blinded.Incomplete outcome data (attrition bias)   All outcomesLow riskA total of 49/1000 pregnant women (4.9%), out of which 28/500 (5.6%) in the chloroquine group and 21/500 (4.2%) in the placebo group were excluded from the final analysis of efficacy against *P. vivax*. Reasons for exclusion were provided.Selective reporting (reporting bias)Low riskNone identified.Other biasLow riskNo apparent risk.

Characteristics of excluded studies \[ordered by study ID\] {#CD000169-sec2-0023}
===========================================================

StudyReason for exclusion[Asa 2008 NGA](#CD000169-bbs2-0020){ref-type="ref-list"}No placebo/no intervention group. Compares chloroquine with SP.[Briand 2009 BEN](#CD000169-bbs2-0021){ref-type="ref-list"}No placebo/no intervention group. Compares SP with mefloquine.[Clerk 2008 GHA](#CD000169-bbs2-0022){ref-type="ref-list"}No placebo/no intervention group. Compares SP with amodiaquine or amodiaquine plus SP.[Deen 2001](#CD000169-bbs2-0023){ref-type="ref-list"}The study is a part of a double‐blinded, placebo‐controlled, village‐randomized malaria transmission‐reduction trial, comparing the efficacy of a single dose of artesunate and SP against placebo. However, target group is the general population (14,017 villagers). Women who were \"thought that they might be pregnant\", were advised not to take the study drugs. Some of them unknowingly took the drugs and their outcomes are reported. There is no specific method of randomization of the pregnant women who \"accidentally\" took the drugs, to ensure similarity of the groups. Also, distribution is uneven: N = 287 in the intervention group versus N =40 in the control group.[Diakite 2011 MLI](#CD000169-bbs2-0024){ref-type="ref-list"}No placebo/no intervention group. Compares intermittent SP: 2 doses versus 3 doses.[Diallo 2007 MLI](#CD000169-bbs2-0025){ref-type="ref-list"}No placebo/no intervention group. Compares weekly chloroquine with intermittent SP.[Dolan 1993](#CD000169-bbs2-0026){ref-type="ref-list"}Trial of impregnated mosquito nets.[Filler 2006 MWI](#CD000169-bbs2-0027){ref-type="ref-list"}No placebo/no intervention group. Compares intermittent SP: 2 doses versus 3 doses.[Gies 2009](#CD000169-bbs2-0028){ref-type="ref-list"}Described as \"a health centre randomized trial\". This study evaluated the IPT‐SP uptake in a community‐based trial where health centres were randomized to one of three arms: IPT‐SP with health promotion, IPT‐SP without promotion and weekly CQ. The purpose was to assess the impact of a village‐based promotional campaign to enhance antenatal clinic (ANC) attendance.[Hamer 2007 ZMB](#CD000169-bbs2-0029){ref-type="ref-list"}No placebo/no intervention group. Compares intermittent SP: 2 doses versus 3 doses[Hamilton 1972 UGA](#CD000169-bbs2-0030){ref-type="ref-list"}This previously included trial was excluded in the updated version because Hamilton and his team administered iron to one of the control groups and folic acid to the other, but nothing was mentioned of iron and folates being administered to women in the intervention group (chloroquine).[Helitzer 1994](#CD000169-bbs2-0031){ref-type="ref-list"}4 clinics trying different methods to achieve adherence; not randomized.[Kayentao 2005 MLI](#CD000169-bbs2-0032){ref-type="ref-list"}No placebo/no intervention group. Compares weekly chloroquine with intermittent SP.[Luntamo 2010 MWI](#CD000169-bbs2-0033){ref-type="ref-list"}No placebo/no intervention group. Compares intermittent SP: 2 doses versus 3 doses.[Martin 1982](#CD000169-bbs2-0034){ref-type="ref-list"}Reported as randomized 100 women, but analysis is by whether women complied, and those that did not comply (37 participants) analysed as a separate group.[McDermott 1988](#CD000169-bbs2-0035){ref-type="ref-list"}Started as a RCT, but discontinued when reports elsewhere noted an association between amodiaquine and agranulocytosis; trial then became an observational study with the 2 arms of the trial combined.[McGready 2001](#CD000169-bbs2-0036){ref-type="ref-list"}Trial of repellent.[Menéndez 2011](#CD000169-bbs2-0037){ref-type="ref-list"}Study done in the context of a randomized, double‐blind, placebo‐controlled trial of IPT‐ SP for malaria prevention (already included, [Menendez 2008 MOZ](#CD000169-bbs2-0008){ref-type="ref-list"}).[Mutabingwa 1993 TZA](#CD000169-bbs2-0038){ref-type="ref-list"}No placebo/no intervention group. Compares weekly chloroquine with daily proguanil.[Naniche 2008](#CD000169-bbs2-0039){ref-type="ref-list"}Study done in the context of a randomized, double‐blind, placebo‐controlled trial of IPT‐ SP for malaria prevention (already included, [Menendez 2008 MOZ](#CD000169-bbs2-0008){ref-type="ref-list"}).[Ouedraogo 2008 BFA](#CD000169-bbs2-0040){ref-type="ref-list"}No placebo/no intervention group. Compares weekly chloroquine with intermittent SP.[Pertet 1994](#CD000169-bbs2-0041){ref-type="ref-list"}Possible RCT; wrote to the authors in 1998; no response.[Randriam. 2011 MDG](#CD000169-bbs2-0042){ref-type="ref-list"}No placebo/no intervention group. Compares weekly chloroquine with intermittent SP.[Schultz 1994 MWI](#CD000169-bbs2-0043){ref-type="ref-list"}No placebo/no intervention group. Compares weekly chloroquine with intermittent SP.[Serra‐Casas 2010](#CD000169-bbs2-0044){ref-type="ref-list"}Study is done in the context of a randomized, double‐blind, placebo‐controlled trial of IPT‐ SP for malaria prevention during pregnancy (already included, [Menendez 2008 MOZ](#CD000169-bbs2-0008){ref-type="ref-list"}), investigating the effect of IPT‐SP on maternal and cord Immunoglobulin G (IgG) levels and comparing antibody levels between intervention groups. The study is mostly about the association between antibody levels and morbidity outcomes, and not focused on the specific outcomes included in the protocol for the review.[Shulman 1998](#CD000169-bbs2-0045){ref-type="ref-list"}Study of impregnated mosquito nets.[Steketee 1996](#CD000169-bbs2-0046){ref-type="ref-list"}Comparison between mefloquine and chloroquine.[Tagbor 2010](#CD000169-bbs2-0047){ref-type="ref-list"}A randomized controlled non‐inferiority trial conducted in Ghana, comparing the safety and efficacy of intermittent screening and treatment (IST), a new strategy for malaria control, and treatment with SP. There were two intervention groups: SP and IST; IST and treatment with amodiaquine+artesunate (AQ+AS), versus the control group ‐ standard IPT‐SP. We excluded this study because a different strategy (not chemoprevention but early screening and treatment) was used in the intervention arm.[Thaler 2006](#CD000169-bbs2-0048){ref-type="ref-list"}Study, comparing riboflavin (not an active antimalarial drug) to placebo.[Tukur 2007 NGA](#CD000169-bbs2-0049){ref-type="ref-list"}No placebo/no intervention group. Compares chloroquine once only followed by weekly pyrimethamine with intermittent SP.[Valea 2010 BFA](#CD000169-bbs2-0050){ref-type="ref-list"}No placebo/no intervention group. Compares intermittent SP: 2 doses versus 3 doses.
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